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The Regulation of Skeletal Muscle Growth via the Myostatin Signalling Pathway
Mohammad Al Khalaf
Myostatin (Mstn) is a negative regulator of skeletal muscle fibre size and satellite
cell proliferation whose role in mature fibre compensatory growth has not been fully
characterized. Myostatin knockout (Mstn-/-) mice display consistently larger skeletal
muscle masses, as well as an overall increase in size and number of myofibres within the
muscle, compared to the wild-type mice. Previous research has shown that Mstn plays a
major role in the attenuation of both the hypertrophic and hyperplasic pathways of
myofibre growth. Immunohistochemical staining of overloaded plantaris muscles was
performed to analyze phenotypic and morphological changes in wild-type and Mstn-/-
muscles. Preliminary results of these analyses indicated a tendency for muscles from
Mstn-/- mice to express an increased number of myofibres, whereas muscles from
Mstn+/+ mice tended to display hypertrophied pre-existing mature myofibres as a
response to the overload stimulus. Additionally, using semi-quantitative PCR and western
blotting, changes were monitored, in mRNA transcripts and protein expression levels, for
some of the major factors involved in muscle growth signalling. Our preliminary results
also showed altered expression of genes and proteins that ultimately translate to increased
satellite cell proliferation and maturation in Mstn-/- muscles. Taken together, myostatin' s
effect on muscle is most apparent in attenuating the hyperplasic growth response in
stimulated muscle, and not the hypertrophic signalling pathway. This is the first in vivo
study to specifically look at the function of myostatin in muscles that are induced to grow
by means of functional overloading.
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The human body is made up of approximately 40% muscle by weight (Gallagher
et al., 1997). Muscle tissue is grouped into three major categories; cardiac muscle,
smooth muscle and skeletal muscle. Cardiac muscle makes up the walls of the heart and
is involuntarily regulated. Smooth muscle is located in the walls of hollow internal
structures such as blood vessels, the stomach, intestines, and urinary bladder, and again it
is mostly involuntarily regulated in the body. Skeletal muscle is primarily responsible for
generating the voluntary movements the body is capable of performing. It is made up
mostly ofmyofibres, as well as connective tissue that make up the tendons (Kääriäinen et
al., 2000). Myofibres are multinucleated, resulting from multiple myoblasts fusing
together during the maturation process to form the long myofibres that make up muscle
tissue. The basic functional unit of myofibres is called the sarcomere, a short repeating
unit made up primarily of myosin and actin proteins that can fold onto each other to
contract the sarcomere (see Figure 1.1). This allows for overall myofibre shortening in

















Figure 1.1: Skeletal Muscle structure diagram. Modified from: Essentials of Anatomy
and Physiology, Elaine Marieb, 8th Edition
Myofibres are classified by the types of myosin heavy chain isoforms they
express within their sarcomeres. There are different classifications for these proteins. The
simplest form categorizes the myosin heavy chain proteins as slow twitch or fast twitch,
slow twitch being the isoforms that employ an oxidative metabolic pathway for
generating adenosine triphosphate (ATP) for energy, while the fast twitch proteins
employ a glycolytic metabolic pathway for generating ATP for its use (Handschin et al.,
2007). The oxidative pathway is initiated during aerobic respiration, meaning oxygen is
utilized, with glucose, to produce ATP, as well as carbon dioxide and water as by-
products. This pathway is carried out in the mitochondria within cells, and this explains
why slow twitch fibres are rich in mitochondria and are therefore characterized by the
red-colored myoglobin content that is sometimes used to describe the tissue. The
glycolytic pathway is initiated during anaerobic respiration, meaning glucose is
metabolized to pyruvate, and the energy released from that reaction is used to produce
ATP for energy. This reaction could occur without the involvement of oxygen in the
cytoplasm, and under anaerobic conditions will produce lactic acid to replenish depleted
nicotinamide adenine dinucleotide (NAD+). While this form of metabolism is faster in
producing ATP for the myofibre to use, it produces only a fraction of the amount of ATP
that the body produces using aerobic respiration. Therefore, the fast twitch fibres are also
known as fatigue-prone cells, showing great contractile force, but for only short periods
of time (Girgenrath et al, 2005).
Myosin heavy chain (MyHC) proteins, which make up the myosin heads on the
overall myosin protein, have at least four major types of isoforms that are expressed in
the sarcomere mature myofibre. Those isoforms are named: 1 (the slowest type of
MyHC), IIA, HX and IIB, (the fastest type of MyHC), (Dunn et al., 1999). Myofibres that
are characterised as "slow-twitch" express MyHC I isoform, while the fastest "fast-
twitch" fibres express MyHC HB. However it is observed constantly that fibres can co-
express some of the isoforms (Michel et al., 2007), such that a myofibre expressing both
MyHC I and IIA, or MyHC HX and IIB, in an attempt to fine-tune the myofibre, and
ultimately the overall muscle, to be in a position to have optimal energy consumption.
There are various pathways that regulate the expression of the different myosin heavy
chain isoforms as well as overall muscle mature size and growth rate.
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Skeletal muscle applies two different mechanisms for repair or growth, named
hypertrophy and hyperplasia (Joulia-Ekaza et al., 2006). Hypertrophy is the mechanism
in which existing muscle fibres grow bigger in diameter and hence total volume causing
the overall muscle to increase in mass. The increase is measured as cross-sectional area,
where the area of the muscle fibre is increased as a result of higher protein production
leading to larger size and increased number of myofibrillars (see Figure 1.1). Much of the
early research reports that myostatin null animal models display a marked muscle
hypertrophy. Hyperplasia is the mechanism in which new muscle fibres are formed,
increasing the overall size of the muscle tissue by adding newly formed myofibres (Seale
et al., 2000). Hyperplasia occurs by activating muscle progenitor cells known as muscle
satellite cells. These cells are stem-like in nature, they are held in a quiescent form in
adult muscle tissue, and when activated, they proliferate, differentiate and fuse to form
new myofibres (Le Grand et al., 2007). Recently a new protein called myostatin was
discovered to have a key role in how muscles grow. It has been shown to have an
inhibitory effect on muscle hypertrophy and hyperplasia, and thus it has become vital to
furthering our understanding of this protein so that muscle related diseases and
syndromes can be better diagnosed and treated in the future.
1.2: Myostatin Gene and Protein
Growth/Differentiation Factor-8 (GDF-8) is a protein first discovered and
identified in 1997 by the team of Dr. Se-Jin (McPherron et al., 1997). Using degenerate
polymerase chain reaction they identified the sequence of GDF-8 and its similarity to
other members of the Transforming Growth Factor-ß (TGF- ß) superfamily of proteins.
The role of GDF-8 was qualitatively determined by generating mice models with a
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disruption of the gene encoding this protein. The results showed that overall body mass
was increased by 30% and that skeletal muscles were the sole contributor to this increase,
showing an increase in muscle mass of 2-3 fold, irrespective of age or gender (McPherron
et al., 1997). These authors showed GDF-8 to be expressed in early embryogenesis stages
and mostly in adult skeletal muscle, with some detectable amounts in adipose tissue. Dr.
Se-Jin Lee coined this new protein by the name of myostatin since it was clear that its
function seemed to be primarily as a negative regulator of muscle growth (McPherron et
al., 1997).
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Figure 1.2: Myostatin protein processing into its active conformation. Modified from:
Rogers et al., 2008
Myostatin mRNA is translated into a 53 kDa protein containing 376 amino acids
(McPherron et al., 1997; Kocamis et al., 2002). It is secreted from the cell to affect
adjacent cells. Therefore, it is identified as a paracrine hormone (Favier et al., 2008). It is
proteolytically cleaved at a site close to its C-terminus, seen in Figure 1 .2, producing a
short active form of the peptide and a long inhibitory pro- peptide domain, with the
shorter peptide homodimerizing to generate its final active state (McPherron et al., 1997;
Kocamis et al., 2002; Armand et al., 2003). Figure 1.3 illustrates the active homodimer
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and the inhibitory site of the pro-peptide domain of the protein. Myostatin is conserved
across many species, showing high degree of homology between human, murine, rat,
porcine, chicken, and turkey sequences (McPherron et al., 1997, Kocamis et al., 2002).
Myostatin null mice show myofibre cross sectional area (CSA) increases of
approximately 50% for the gastrocnemius muscle of 1 0 week old mice as an example
(Lee, 2007). Total body fat also steadily decreases over time as Mstn ~'~ mice age, even
though metabolic rate is reduced and food intake unchanged (Joulia-Ekaza et al., 2006),
as tested by monitoring blood serum levels of leptin, a biological marker for total body
fat accumulation. This could imply other roles for myostatin in the body, not only in
skeletal muscles. Some of the research in the field that is looking at myostatin's role in
adipose tissue, for example Dr. Mehan's group (Allen et al., 2008), show that there are
several questions pertaining to myostatin-signalling in adipose tissue. Using obese mice
as a model, they looked at levels of myostatin, activin receptor HB and Follistatin-like
gene 3 (FSTL3), three major components of the myostatin pathway, in visceral and
subcutaneous fat tissue. Their results showed that compared to wild-type levels,
myostatin and activin receptor HB levels increase in VSF and SQF while FSTL3 levels
decrease in obese mice, suggesting a role for myostatin in inhibiting the overall basal
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Figure 1.3: Summary of known signalling pathway initiated by myostatin. Modified
from Joulia-Ekaza et al., 2006
The myostatin homodimer binds to a serine-threonine receptor kinase known as
activin receptor IIB (ActRIIB) that initiates intracellular signalling involving Smad
proteins (Baumann et al, 2003). The name of this class of proteins comes from the fact
that they are homologs of a protein found in C. elegans named SMA and a protein found
in Drosophila named mothers against decapentaplegic protein MAD, therefore the
acronym SMAD was coined. The receptor is found on the cell membrane of myofibres,
and is named after another GDF protein called activin, a protein first discovered to have a
role in the development of the pituitary follicle-stimulating hormone in the reproductive
axis. It has also been shown more recently to be involved in neuron development (review:
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Tsuchida et al., 2008). After that pathway was elucidated, myostatin binding to the
receptor was reported, which explains the non-related name of the receptor to myostatin.
Binding of the myostatin homodimer to ActRIIB causes it to associate with activin
receptor-like kinase 4 (ALK4) receptor, which then gets trans-phosphorylated from
ActRIIB, allowing it to phosphorylate Smad2 and Smad3 (Joulia-Ekaza et al., 2006).
Smad proteins are described as intracellular mediators. They become phosphorylated by
the receptor kinases and start a cascade of secondary and tertiary messages that
activate/deactivate specific nuclear transcription factors that affect gene expression in
muscles (Joulia-Ekaza et al., 2006). Myostatin activates Smad2 and Smad3 which
dimerize and can sometimes interact with co-Smad4 which potentiates the signalling
(down-stream of 2/3). Smad7 and small ubiquitination regulatory factor 1 (Smurfl) are
inhibitory smads to this pathway and myostatin is shown to induce expression of Smad7
causing a self-inhibitory feedback loop to be possible (Joulia-Ekaza et al., 2006).
For myostatin to be in its mature active homodimer, it must be proteolytically
cleaved by furin, seen in Figure 1 .2, a pro-protein convertase (Anderson et al., 2008).
There is not much known about the specifics of this pathway, but Dr. Whitman's group
(Anderson et al., 2008) published research showing some key events that occur in the
pathway leading to myostatin maturation. Using immuno-precipitation techniques, they
showed that when myostatin is first translated into the inactive full-length pro-peptide,
53kDa in size ( which they call pro-myostatin), it would bind to a protein called latent-
transforming growth factor ß binding protein 3 (LTBP3) in the endoplasmic reticulum. It
would shuttle the pro-myostatin to the Golgi and then out into the extracellular matrix.
There, LTBP3 would dissociate from the pro-myostatin peptide, which would then bind
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to another pro-myostatin peptide forming a homodimer, and furin would cleave the N-
terminal pro-peptides, (4OkDa), from myostatin's C-terminal active site (26kDa) within
the homodimer (Anderson et al., 2008).
Myostatin's role in regulating muscle growth is being deciphered from many
angles, and progress is clear and promising. An important aspect to consider is that
myostatin has been shown to play a role in diseases such as AIDS, cachexia, scleraxis,
and fast-twitch myofibre atrophy disease (Kocamis et al., 2002, Baumann et al., 2003,
Mendias et al., 2008, Wojcik et al., 2008). In all of these diseases myostatin's serum
levels are increased leading to muscle wasting in humans. A study by Dr. Faulkner's
group (Mendias et al., 2008) also showed that myostatin-null mice showed muscles with
weaker, more brittle tendons than wild-types. However, no other group has reported the
same finding. As well, there is compounding evidence that shows knocking out myostatin
in the mouse model for Duchenne Muscular Dystrophy displays a rescuing effect
countering this muscle wasting disease (for review see: Haidet et al., 2008; Bradley et al.,
2008).
1.3: Myostatin Gene Regulators
Studies have been performed to analyze the molecules that regulate myostatin's
expression in muscle cells. It is known that myostatin is a negative regulator of muscle
growth, however what is the purpose of producing a protein with such a role? To
understand its purpose, one must examine the activators of this protein and identify the
origin of their signalling. Dr. Sharma's group studied the promoter region of the
myostatin gene in murine and cattle models. By designing various constructs of the
10
myostatin promoter region and linking them to a reporter (luciferase) and then injecting
these into the quadriceps ofmice, they were able to see how removing part of the
promoter would affect the expression of myostatin protein in vivo (Salerno et al., 2004).
This would help to identify certain regions of the promoter and to characterise the
molecule involved with that specific promoter region. Using this method, these authors
have identified regions for binding myogenic determination factor (MyoD) and Myocyte
Enhancing Factor (MEF2) to the promoter (Salerno et al., 2004). These two transcription
factors are both involved in muscle growth. They are upregulated when muscle fibres are
in the process of developing, therefore it follows that they also signal the upregulators of
myostatin as well since uncontrolled growth is detrimental to the body, wasting energy
and resources to build muscles that are unnecessarily large. Myostatin may have a role as
a molecular braking system to this acceleration of growth.
Other studies have also shown that the myostatin promoter has a binding region
for glucocorticoids, called the glucocorticoid response element region (Joulia-Ekaza et
al., 2006; Gilson et al., 2007). This feature explains the negative effects of injecting
glucocorticoids since glucocorticoids promote proteolytic pathway initiation in muscles.
The aforementioned group investigated whether myostatin gene deletion would lead to
less atrophy caused by glucocorticoid administration. The deletion prevented
dexamethasone-induced atrophy, characterised by measuring both muscle weight and
CSA ofmyofibres of Mstn -/- mice. The loss of functional myostatin also led to the
inhibition of Muscle -specific Ring Finger 1 (MuRFl), Atrogin-1, Forkhead box protein
3a (Foxo3a), and Cathepsin upregulation upon dexamethasone treatment (Joulia-Ekaza et
al., 2007). Cathepsin is a lysosomal enzyme known to be involved in degradative
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pathways (Joulia-Ekaza et al., 2007). MuRFl and atrogin-1 are ubiquitin ligases that
target proteins for proteolysis (Joulia-Ekaza et al., 2007), while Foxo3a is a transcription
factor that regulates the expression of the genes encoding these two proteins (Joulia-
Ekaza et al., 2007). The conclusion from this paper is that myostatin is needed to induce
catabolic activity/proteolytic pathways in skeletal muscles.
1.4: Myostatin Antagonist: Follistatin
Most, if not all, proteins in vivo have antagonists that counteract or inhibit their
actions. In the myostatin signalling pathway follistatin plays this role, acting directly to
inhibit the myostatin pathway, by binding to myostatin and activin receptor HB (Lee,
2007). Follistatin is a protein, first identified as a secreted hormone from the gonads that
inhibits the actions of follicle stimulating hormone (FSH) during reproduction and
developmental processes in the body (for review see Lin et al., 2003). More recent
research has unrevealed a wider role for follistatin as an inhibitor to the TGF-ß
superfamily ofproteins. Se-Jin Lee reported that in mouse models that have myostatin
knocked out and follistatin over-expressed, the overall mass/size of skeletal muscle is
quadrupled compared to wild-type mice (Lee, 2007). Follistatin null mice show a 2-3
reduction in overall skeletal muscle mass. Dr. Chanoine's group was interested in
showing the reciprocal interactions between follistatin and myostatin (Armand et al.,
2003). In their study, they used denervation and injections of cardiotoxin, (a poisonous
compound found in cobra venom), to the soleus to test the levels of the mRNAs coding
for myostatin and follistatin over a number of days post-intervention. They showed that
while myostatin levels initially decrease presumably since the myofibres are atrophying,
there would not be much need to transcribe more myostatin, follistatin levels increased,
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presumably to quickly attempt to regenerate and grow new myofibres to counteract the
loss. Other than follistatin, there are a number of peptides that inhibit myostatin in a
similar fashion (see Figure 1 .4). Follistatin-like related gene (FLRG) and the pro-peptide
of myostatin (the large portion that gets cleaved to make the active homodimer) are both
known to interact with the myostatin active homodimer to inhibit its ability to signal
through the activin receptor IIB and Smads (Hill et al., 2002). This was discovered when
Dr. Qiu's group performed mass spectrometric analysis of isolated myostatin protein in
serum by binding it to JA 16 coupled beads, JA 16 being the monoclonal myostatin
antibody, and running the serum containing native myostatin through affinity
chromatography (Hill et al., 2002). They were able to isolate and characterise the
different peptides that were associated with myostatin, and found that most of the serum
myostatin was coupled to either FLRG or the pro-peptide of myostatin (reviewed by:















Figure 1.4: Summary diagram showing the multiple peptides that can bind and
inhibit myostatin from interacting with its receptor. Modified from Bradley et al. ,2008
Krasney's group (Schneyer et al., 2009) investigated the follistatin protein to
further understand how it binds to myostatin and the Activin IIB receptor. The paper
identifies the binding domain of follistatin that is specific for myostatin being different
from the binding domain of follistatin specific to activin receptor. Follistatin and FLRG
bind and neutralize activin irreversibly, and bind and neutralize myostatin with three to
five fold less affinity. Using in vitro cells (26 follistatin mutants), they report that
follistatin domain 1 (FSDl) is the domain necessary for myostatin binding and FSD2 is
necessary for activin receptor IIB binding.
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Thiessen's group has published another study addressing the role of follistatin in
muscle growth. In this study, the group showed that overexpression of follistatin
increases the cross-sectional area (CSA) of muscle fibres, as well as total DNA content
(Gilson et al., 2009) which they use as a measure of satellite cell proliferation, since more
cells would lead to more DNA content as they measured it. The study showed that the
overexpression of follistatin even in myostatin null transgenic mice induced an even
greater increase in muscle mass and CSA of fibres (Gilson et al., 2009). Thus, his study
further characterises follistatin as an antagonist to myostatin's role in muscle growth.
1.5: Hypertrophy: The Akt pathway
The Akt pathway in muscle growth has been extensively researched and is
regarded as the major pathway involved in muscle hypertrophy (Amirouche et al., 2009).
The link between the Akt pathway and the myostatin pathway has been studied by a
number of groups in efforts to discover if there is an inhibitory role by myostatin on this
hypertrophy-inducing pathway. Dr. Rosenzweig' s group has published recently a study
showing Akt levels are higher in myostatin knockout muscles compared to those of wild-
type (Morissette et al., 2009). Additionally, they have shown that phosphorylated Akt
(active) is higher in those knockout muscles as well. These authors conclude that
myostatin does in fact have a role in inhibiting the Akt pathway based on their research
and, therefore, myostatin works to block hypertrophy by acting on its main signalling
protein, Akt.
Another group that has examined the link between myostatin and the Akt pathway
is headed by Damien Freyssent. In their recently published paper, they demonstrate that
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overexpressing myostatin in tibialis anterior (TA) muscles causes atrophy to occur in
those muscles (Amirouche et al., 2009). Electrotransfering myostatin loaded plasmids
into the TA muscles and then extracting muscles after 7 days allowed them to look into
the effects of overproducing the protein. They found that both Akt and one of its
downstream target S6 protein was both downregulated in the myostatin overexpressing
muscles. That coupled with the overall muscle weight decrease that shows the after
electrotransfering was seen as evidence of the link between myostatin and the Akt
pathway.
The logical question that follows is how does myostatin negatively regulate
muscle fibre growth? It was shown that hypertrophy occurs when myostatin is altered.
The next step was to see whether myostatin controls muscle fibre number, since muscle
can grow in mass by making more fibres, a state known as hyperplasia (McCroskery et
al., 2003). To answer this question, one must consider satellite cells. These are quiescent
stem-like cells found in muscles, which can, when activated, grow and differentiate into
adult myofibres (Seale et al., 2000). These are used by the body to recover from muscle
injury and increase muscle size triggered by exercise (Seale et al., 2000). McCroskery' s
group showed first that myostatin is in fact expressed in satellite cells (Wagner et al.,
2002). They also showed that Mstn-/- cultured cells extracted from the tibialis anterior
muscle had more satellite cells present per 100 myonuclei, and faster myoblast
proliferation than wild-type cells. Finally, the addition of exogenous myostatin inhibited
satellite cell activation and myoblast proliferation in vitro. These data suggest that
myostatin is involved in the hyperplasic response within muscles; when absent, myostatin
causes muscle to increase myofibre number.
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1.6: Hyperplasia: Satellite Cells




Figure 1.5: Satellite cells go through a number of phases before reaching mature
myofibre status. Modified from Le Grand et al., 2007.
The transformation of a satellite cell to an adult myofibre, it would have to go
through multiple stages, (Figure 1 .5), controlled by certain proteins that are temporally
expressed to drive this maturation process (Le Grand et al., 2007). Satellite cells exist as
quiescent mono-nucleated small entities found on the periphery of mature myofibres
(Seale et al., 2000). Once activated, satellite cells are committed to proliferate and the
majority of the newly formed satellite cells differentiate into myoblasts and finally fuse to
form myofibres (Kuang et al., 2007). Not all of the proliferating satellite cells mature to
myofibres however, as some are arrested after proliferation and kept dormant in a process
called self-renewal, therefore ensuring that there are enough satellite cells for future
needs (Olguin et al., 2004). Paired-box transcriptional factor 7 (Pax7) is a conserved
marker for quiescent satellite cells studied extensively by Dr. Rudnicki's group using
immunofluorescence microscopy in myofibre cell cultures (Kuang et al., 2007). It plays
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an important role in the development and function of these satellite cells. Pax7 null mice
show premature lethality and a complete lack of satellite cell population (Seale et al.,
2000),as deduced using electron microscopy to visualise cells from wild-type mice and
Pax7-/- mice (Chen et al., 2003). Pax7 expression is seen in satellite cells as they progress
from quiescent to activated and proliferating cells, but once the cells reach the myoblast
maturation stage, the expression of Pax7 is turned off and the cell is considered mature
(for review see Shi et al., 2006). The nature of Pax7 expression makes it an optimal target
marker for satellite cell identification, both at the level of gene expression and final
protein product. Many researchers use Pax7 expression analysis as a basis for assessing
satellite cell activation and maturation (Kuang et al., 2007, Seale et al., 2000, Le Grand et
al., 2007). While Pax7 is expressed early in the life of a satellite cell, once activated, Pax7
is downregulated and myogenin expression is upregulated in those cells, making it a
prime target to test for mature myofibre increase (Day et al., 2009). A study by Olwin and
collegues states that Pax7 acts in a manner that prevents the to maturation of satellite
cells, and it is only after Pax7 expression is turned off, that the process of differentiation
and maturation of satellite cells into myotubes occur (Olguin et al., 2004). This
conclusion was reached after immunofluorescence analysis of proliferating and maturing
myoblasts showed Pax7 is not expressed in the more mature myoblasts as compared to
the proliferating and quiescent satellite cells.
Once activated, satellite cells express other signalling molecules called myogenic
regulatory factors (MRFs), which are transcription factors that regulate myogenesis,
promoting the transition from quiescent to mature myofibre (Yafe et al., 2008). When
activated and committed to differentiate beyond the quiescent phase, satellite cells begin
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to express myogenic factor 5 (Myf5) and myogenic determination factor (MyoD) (for
review see Seale et al., 2000). These factors induce proliferation of satellite cells.
Following this proliferation phase, these cells begin to express myogenin and muscle
regulatory factor 4 (MRF4), which are factors that drive the cell differentiation and
maturation to adult myofibres (for review see Le Grand et al., 2007). All MRFs regulate
gene expression by binding to ?-box motifs, highly conserved stretches of DNA sequence
(CANNTG) found in the promoter region upstream ofmuscle specific genes, and turning
on expression of specific gene targets that are involved in myofibre formation (Yafe et
al., 2008). It is prudent to note that looking at all the research regarding satellite cells put
together, it becomes clear that not all satellite cells are exactly the same. There is
heterogeneity among satellite cell populations, with some being more readily committed
to myogenic proliferation while others are in a noncommitted form. This phenomenon is
discussed in more detail in Rudnicki's review paper (Kuang et al., 2007). Suffice it to say
that it is not surprising then that while the overall pathway for satellite cell activation to
maturation is described rather well by examining the MRFs, there are clearly other
factors that come into play as well, and not much is known about the exact signalling of
these pathways.
The role ofmyostatin in satellite cell-related muscle fibre growth is a
controversial one. Some research indicates that myostatin is responsible for arresting
satellite cells in quiescent stage, therefore preventing them from proliferating and leading
to increased muscle fibre numbers (Amthor et al., 2006), this work was done by Dr.
Patel's group, and it shows that addition of myostatin protein to muscle cell culture
causes a downregulation of MyoD, Myogenin, and Myf5 but not Pax7 (the quiescence
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marker). This supports the notion that myostatin null mice would have greater satellite
cell proliferation and consequently, a greater number of mature fibres, the process of
hyperplasia. The same group, however, published another study stating that myostatin
does not act on satellite cells, and that hypertrophy of existing fibres is the main outcome
of blocking myostatin action (Amthor et al., 2009). They concluded this after counting
the overall number of myofibres in the EDL muscle in wild-type and myostatin null mice
and simultaneously analyzing the CSA ofthose fibres. They found that the CSA in the
myostatin null mice does, in fact, differ while the overall number of fibres is not
significantly different between wild-type or knockout mice. Other research shows that
myostatin up-regulates/activates the cell cycle arrest protein p21, thereby limiting the
proliferation of satellite cells (Manceau et al., 2008). This conclusion was reached when
the group performed myostatin overexpression and myostatin inhibition experiments on
chick and mouse embryos. Using immunofluorescence, the aforementioned author
reported that in the increased myostatin pool of cells, less proliferation of satellite cells
was observed and more p21 was apparent. In the myostatin deficient pool of cells the
opposite was true, more proliferating satellite cells and less p21 expression was observed.
Dr. Kambadur's group published a study focusing on myostatin' s role in inhibiting Pax7,
and found that adding myostatin to cultured developing myoblasts decreased their
expression of Pax7 by 80% (McFarlane et al., 2008). In the same study they show that
myostatin-null cultured cells express more Pax7+ quiescent cells than the wild-type cells
do further showing the early involvement of myostatin in regulating the self-renewal
abilities of satellite cells. While myostatin is definitely characterized as a protein that
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inhibits the overall growth of muscle fibres, the debate continues to be whether it is
primarily through increased hyperplasia or hypertrophy that myostatin null muscles grow.
Dr. McCullough's group investigated the role of myostatin in satellite cell
activation (Dasarathy et al., 2004). They studied myostatin and insulin-like growth factor-
1 (IGF-I) expression (a known player in the muscle growth pathway, stimulating AKT-
PI3K pathway), and how that would affect the expression of cyclin-dependent kinase
inhibitor (CDKI p21), myf5, MyoD, and Myogenin (Dasarathy et al., 2004). These are all
stimulators of satellite cell differentiation; CDKI p21 is controlled in opposite fashions by
myostatin and IGF-I . The results showed that muscle wasting due to induced liver
cirrhosis of rats had myostatin, ActRIIB, and CDKI p21 all increased one to three fold,
while MyoD, myf5, and myogenin all decreased two to three fold, also IGF-I, and IGF-I
receptor decreased (Dasarathy et al., 2004). These data show that myostatin does, in fact,
inhibit satellite cell proliferation and differentiation, thereby retarding the ability to make
new myofibres. This supports the idea that hyperplasia does occur in the myostatin null
model. Other research has shown that myostatin arrests myoblast transition from Gl to S
phase and from G2 to M phase in the cell cycle (for review, see Kocamis et al., 2002).
Some research shows that myostatin inhibits Pax-7. Using in vitro assays on C2C12 cells,
Dr. Kambadur and collegues showed that myostatin null clones showed higher expression
of Pax-7, while increasing myostatin in culture decreased Pax-7 detection using western
blots, as well as immunohistochemical fluorescence detection (McFarlane et al., 2008).
This provides further insight into how myostatin directly affects satellite cells in muscles
by promoting the quiescence of satellite cell activation and proliferation and, therefore,
overall muscle ability to grow or regenerate.
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Another study from Dr. Kambadur's group shows that fast fibre types (Myosin
heavy Chain HX and IIB) express MyoD in much greater amounts than slow fibre type
(MyHC I and IIA). This could explain why Myf5 and MyoD appear to have overlapping
functions in inducing satellite cell proliferation (Hennebry et al., 2009) since MyoD
would act more specifically on the fast fibres only. In this paper, myostatin is reported to
negatively regulate MyoD, showing that its absence allows for higher expression of
MyoD in bicep, as well as tibialis anterior muscles. Their results show that myostatin is a
direct inhibitor of satellite cell proliferation, and in myostatin null mice the ability for
these quiescent cells to proliferate and mature is enhanced through higher expression of
MyoD and its ability to turn on expression of genes related to cell activation and
proliferation. In this same paper, Kambadur's group also shows that in the absence of
myostatin, another transcription factor, myocyte enhancer factor 2 (Mef2) is
downregulated, as is Calcineurin. The latter observation was reported by Dr. Michel and
his collegues earlier (Dunn et al., 1999). Both of these proteins are known to be inducers
of the slow fibre type generation, and their downregulation explains why in myostatin
null mice, there is a decrease in slow fibre numbers. Dr. David Goldhammer's group also
studied satellite cell proliferative action as it relates specifically to MyoD, and their study
shows that MyoD is expressed in committed proliferating satellite cells, and its
expression was maintained through to mature myofibres, reaffirming the fact that MyoD
and Myf5 have an overlapping function that is distinct from Pax7 (Kanisicak et al., 2009).
1.7: Myostatin and Calcineurin
While the IGF-Akt pathway is the most well known signalling pathway leading to
skeletal muscle hypertrophy, there are other pathways that contribute to this physiological
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result. In the last decade several studies have been published linking muscle hypertrophy
to calcium ion fluctuations and more specifically the actions of calcium on the calcineurin
(Cn) pathway (Dunn et al., 1999). In their study, using inhibitors of calcineurin, Dr.
Michel's group showed a link between calcineurin and the expected fibre-type switching
to slow fibres associated with plantaris overload. They also show that when treating the
muscle with the calcineurin inhibitor cyclosporine A (CsA), there was a marked
inhibition of myofibre hypertrophy, which further links Cn to muscle growth pathways.
Dr. Engvall's group treated C2C12 cells with metalloprotease inhibitors, known as
HIMPs, and examined the effect on muscle cell growth and maturation (Heut et al.,
2001). Using TAPI and BB-3103, two known HIMPs, they showed maturation from
myoblasts to multi-nucleated myotubes and hypertrophy measured as cell diameter
increases (Heut et al., 2001). They introduced proteins known to be involved in the
calcineurin pathway for muscle cell growth, specifically IGF-I, cyclosporine A, and
calcineurin. While there was no change to cell culture sizes with the addition of HIMPs,
introduction of these metalloprotease inhibitors did cause an increase in the full-length
myostatin (the pro-peptide) and, therefore, an attenuation of the proteolytically cleaved
active homo-dimer ofmyostatin. Taken together their data suggests that HIMPs act on
myostatin and not the calcineurin pathway to allow for cell hypertrophy.
Dr. Wackerhage's group isolated whole cell proteins from extensor digitorum
longus and soleus muscles from rats. Using antibodies specific to signalling pathways
known to be involved in muscle cell growth, they compared the concentrations of these
proteins to show the difference between fast and slow muscle fibre signalling pathways
(Atherton et al., 2004). Their results showed that EDL has 1 .43 times the amount of
23
calcineurin, 1 .95 times more myostatin, 1 .44 times more Akt and 6.86 times more
p70S6K compared to soleus. The EDL showed lower amount of extracellular signal
regulated kinase (ERK) compared to soleus muscle (ERKl 0.38, ERK2 0.61, ERK6 0.15)
as well as lower amounts of NF-kB (0.32) and GSK3ß (0.69). Overall this paper showed
that fast (glycolytic) muscle fibres have different concentrations of important signalling
proteins as compared to slow (oxidative) muscle fibres.
Dr. Yasuhara's group treated mice with cyclosporine A (CsA) injections into the
TA, over a progressive time-course of 1, 2, 4, 6, 9 and 14 days. Using RT-PCR, western
blots and immunohistochemistry, they monitored the changes in several proteins involved
in the growth and atrophy pathways in muscle cells (Sakuma et al., 2005). Their data
showed that CsA injections showed a significant upregulation ofmyostatin, as well as
Smad3 and TGF-ß2. This is of great interest to us since it suggests that there might be in
vivo proteins that can have a role similar to CsA, inhibition of the hypertrophy inducing
calcineurin pathway and upregulation to the negative regulation/atrophy inducing
myostatin pathway.
Several of the studies done on myostatin were performed by James Reecy's
group. Using microarray assays and proteomic profiling, they identified hundreds of
genes and dozens of proteins that express differently in myostatin null muscles as
compared to wild-type muscles (Steelman et al., 2006, Ilham et al., 2009). In these
studies they show that generally there is a definite switch in myostatin null muscle away
from oxidative pathways (employed by slow fibre types) to the glycolytic pathways
(employed by fast fibre types). This is further illustrated by Dr. B Spiegelman's group,
where they show using fluorescence microscopy a 30% increase in myosin heavy chain
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IIB fibres (fast fibres) and in HX in myostatin knockout mice as compared to wild-type
mice (Handschin et al., 2007).
Another study from Yasuhara's group showed that CsA injection blocked
mechanical overload of the soleus muscle, achieved by surgical ablation of the ipsilateral
gastrocnemius muscle (Sakuma et al., 2008). In this paper they show Mef2c and
myogenin are down-regulated both at the mRNA and protein levels following 4 and 1 0
days of mechanical overloading performed on CsA injected muscle. This result is
noteworthy because McCullough's group (Dasarthy et al., 2004) had shown that the
myostatin gene has binding sites for myogenin as well as MyoD, Myf5. This is a further
indirect link between the calcineurin and myostatin pathways, raising questions
concerning whether there are any in vivo molecular signals that can have the same dual
role that CsA appears to have on these pathways.
1.8: Myostatin and Muscle Atrophy
With compounding evidence showing the effects of myostatin on muscle growth,
researchers set out to understand the role of myostatin in muscle atrophy. What might be
the role of myostatin in muscle wasting? Is it directly linked to upregulation of
proteolytic pathways in muscle, or not. If muscles are growing, would myostatin be
downregulated because of its link to proteolysis within muscles? These questions led
have researchers to investigate if there was a link between myostatin and muscle atrophy.
Atrophy is described as a decrease in muscle mass due to protein degradation
(proteolysis) is stemming from the disuse of muscle or from a diseased state. Muscle
fibres being excitable cells would not be able to survive if not stimulated. Therefore,
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using models that inhibit or hinder muscle stimulation, such as sciatic nerve denervation,
or hind-limb suspension, as well as drug administration (glucocorticoids and neurotoxins)
can be helpful models to test atrophying muscle in in vivo and in vitro experiments.
The molecular signalling pathway that is most relevant to muscle atrophy is
known to go through the Forkhead family of transcription factors, also known as
Forkhead boxes, or Foxo's. These are transcription factors that bind to and arrest the
transcription of genes involved in the proteolytic catabolism ofmuscle cells (for review
see: Zhang et al., 2007). Specifically, Foxola and FoxoSa are shown to be involved in
muscle fibre atrophy by arresting the transcription of ubiquitin ligase genes MuRF and
MAFbx (also known as atrogin-1). When phosphorylated, FoXo is translocated out of the
nucleus promoting the transcription of these ubiquitin ligases is allowed to occur. The
ubiquitin ligases can then begin ear-marking muscle fibre proteins with multiple
ubiquitins which then signal and direct proteins to be degraded by the massive
proteosome complexes that breakdown proteins into amino acids that can be recycled for
other uses (for review see Nader et al., 2005).
To link myostatin to atrophy, Dr. Fei Ding's lab examined a time-course
expression profiles of myostatin after denervation, a model known to cause muscle
atrophy due to disuse of the excitable muscle fibres (Shao et al., 2007). As deduced from
RT-PCR and protein expression experiments, a marked increase for mRNA and
myostatin protein was observed, peaking between days 3 and 7 (for mRNA) and days 7
and 14 (for protein), suggesting the strong correlation between myostatin presence and
muscle atrophy due to denervation.
26
Dr. Thissen's group tested the effect of injecting the glucocorticoid drug
dexamethasone into the tibialis anterior, gastrocnemius, and soleus muscles of myostatin
knockout mice versus wild-type mice, and their results showed that dexamethasone did
not cause atrophy in muscles where myostatin is not present, further suggesting that
myostatin is involved in the atrophy pathway (Gilson et al., 2007). They also showed
that there was a greater increase of FoXo3a, MuRFl, atrogin-1, and Cathepsin L in wild-
type mice versus myostatin knockout mice. This suggests that myostatin does have a role
in the FoXo signalling pathway for protein degradation. Dr. Freyssenet has reviewed the
potential link between myostatin and the Foxo pathway (Favier et al., 2008). The
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Figure 1.6: Hypothesized interaction between myostatin and Foxo leading to
protein degradation. Modified from Favier et al., 2008
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Dr. Unterman's group tested the relation between FoXo and myostatin in vitro by
mutating the myostatin promoter region in C2C12 cells, which is hypothesized to be the
binding site of FoXo, and noticed a significant decrease in myostatin promoter activity
using luciferase and GFP as assay markers for protein activation (Allen et al., 2007). This
suggests that myostatin is a downstream effector protein of the Foxo signalling pathway
for muscle atrophy, as shown in Figure 1 .6. The study also examined the protein levels of
myostatin, Foxol, and activin receptor IIB in fast versus slow muscles. Consistent with
previous findings, all these proteins were found elevated in fast muscles as compared to





Studies mentioned earlier (Amthor et al., 2009, Gilson et al., 2009) lend their
support to the idea that myostatin controls muscle growth by inhibiting or attenuating the
hypertrophy pathways in muscles. Other groups, such as the Kambadur and Sharma
(McCroskery 2003 & 2005, Salerno 2004, McFarlane 2005 & 2008, Hennebrt 2009) and
Cabello groups (Joulia-Ekaza 2006 & 2007) published studies that support the idea that
myostatin is involved in inhibiting hyperplasia by attenuating the proliferative capacity of
muscle satellite cells. There are also studies that propose a dual role for myostatin in
regulating both hypertrophy and hyperplasia. Dr. Se-Jin Lee, the first to characterize
myostatin as a protein involved in muscle signalling, and the designer of the myostatin
knockout mouse model, states that both hypertrophy and hyperplasia are inhibited by the
actions of myostatin (Lee 2001 & 2007).
Evidence from all of the research mentioned above can be summarized to suggest
that under normal maturation conditions, alterations to myostatin levels in vivo as well as
in vitro cause an increase in myofibres size and number. However little is known when
the growth rates are altered to test how myostatin' s inhibition is affecting the pathways
involved. Specifically, it is not understood whether inhibiting myostatin and inducing
growth stimuli will lead myofibres in vivo to react by up-regulating pathways involved in
hypertrophy or hyperplasia, and how different are these pathways from wild-type
myofibres with their myostatin levels un-interfered with prior to the growth stimulus
induction. To state more clearly: Does genetic manipulation resulting in the genesis of
myofibres lacking myostatin cause a significantly altered method of reacting to growth
stimuli as compared to wild-type myofibres, or do myostatin null fibres react in the same
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manner as wild-type fibres when facing a similar growth stimulus. Our research group set
out to elucidate the true effect of myostatin in vivo and the subsequent reaction of these
myofibres to a substantial growth stimulus in the form of functional plantaris
overloading.
2.2: Objective and Hypothesis
To further understand the role of myostatin in regulating muscle growth, a study
was initiated in our research lab that concentrated on comparing myostatin null mice to
wild-type mice and how the plantaris muscle is affected by the lack of myostatin or in its
presence. Using the same knockout mouse model that was generated by Dr. Se-Jin Lee,
we set out to study muscle growth over short, intermediate, and long periods of time,
concentrating on deciphering the pathway of growth that muscle cells would take in the
presences or absence of myostatin. The objective was to try to better characterize the
method of growth that myostatin null muscle cells undertake to achieve their enhanced
phenotype of larger sized muscles as compared to wild-type muscle cells. Specifically,
we wanted to observe whether the preferred path of muscle growth was hypertrophic in
nature, meaning increased size of pre-existing cells, or hyperplasic in nature, meaning
increased proliferation of cells adding new fibres to the muscle. We hypothesized that the
hypertrophic and hyperplasic growth pathways will be more potentiated in myostatin null
mice as compared to their wild-type counterparts. Meaning, we proposed that myostatin
was a type of "molecular braking system" that would slow down both types ofmuscle
growth, and removing this protein will result in the ability to use both types of growth
pathways more often. As it was said earlier in the introduction, there seems to be some
controversy regarding what pathway myostatin is involved in downregulating in wild-
type muscle, and we attempted to produce a set of experiments that would lead to
deciphering this question.
2.3: Experimental Design
In order to study muscle growth in mice, there can be several experimental
designs that have been utilized previously. Some include voluntary or involuntary
exercising, like rolling exercise balls or cage wheels, also shallow pool swimming is
utilized by some groups. However, while these designs do show measurable results, in
our group we sought an experimental method that would cause maximal effect on the
muscle studied, in this case the plantaris muscle. Therefore, we employed the surgical
operation known as plantaris functional overloading (Dunn et al., 1999). Used for
decades, the compensatory overloading of the plantaris muscle is achieved through the
surgical removal of the synergistic muscles, the soleus and gastrocnemius that are found
surrounding the plantaris muscle in the calf of the hind limbs. By removing these two
muscles, and then carefully suturing the limb and allowing the mouse to regain
consciousness, the whole weight of the mouse then falls on this one muscle whenever the
mouse utilizes its hind limb to move or stand (Dunn et al., 1999). This permanent added
weight on the plantaris acts as a permanent method of increasing the workload on the
muscle, allowing for rapid growth until the muscle plateaus (usually reaching double the
original size) at a point when it reaches the proper size to compensate for the lack of
soleus and gastrocnemius (Dunn et al., 1999).
Overloading was allowed for certain predetermined periods of time, a short
overload period of three days, an intermediate overload period of two weeks and a long
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overload period of six weeks. These time points would serve to help us understand the
changes that occur from a relative beginning of the overload period, to a relative ending
of the overload period, when the plantaris has presumable reached its full compensatory
ability for the lacking gastrocnemius and soleus. When the period of overload is reached,
the plantaris is extracted from the anesthetised mouse and weighted, then it is stored in -
86°C freezers either in Eppendorf vials or with cutting compound (O.CT) surrounding it
to preserve it for histological cryosectioning at a later point. Histological and biochemical
experiments are then performed using these stored tissues so that we can more
specifically analyze the differences in muscle growth patterns between the myostatin null
mice to the wild-type mice. Details of the experiments performed are found in the
Materials and Methods section.
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3: Materials and Methods
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3.1 : Transgenic Mice Models and Breeding
The main strain of wild-type mouse used for this study was C57/BL6 purchased
from Charles-River laboratories, and the myostatin null (Mstn_/") mice from C57/BL6
background strain with a disruptive neomycin insert in their myostatin gene (McPherron
et al, 1997). Heterozygotes (Mstn+/~) were donated by Dr. Se-Jin Lee (Johns Hopkins,
MD). Breeding of male and female heterozygotes resulted in 25% progeny that lacked
functional myostatin and subsequent Mstn-/- mice were generated from mating those
homozygote offspring. Other transgenic animals used in this project were: CnA* mice
generated from C57/BL6 background strain over-expressing a constitutively active form
of the Calcineurin A subunit due to absence of an auto inhibitory domain (Dunn et al,
2000); CaMBP mice from CDl (white) wild-type mouse background strain over-
expressing a calmodulin binding protein (Dunn et al, 2000); PV-HA mice on from CDl
background strain over-expressing parvalbumin, a calcium buffering protein that
sequesters internal calcium (Corin et al, 1 994); NFATc2-/- mice from Balb/c (white)
wild-type mouse background strain null for the Nuclear Factor of Activated T cells c2
isoform donated by Dr. Grace Pavlath (Hodge et al, 1996).
Whenever a strain was to be studied, the sex and age were matched up with a
wild-type strain of the same background as the generated transgenic strain. This was done
to minimize the number of variables that differ from mouse to mouse.
3.2: Plantaris Functional Overloading Procedure
All mice studied in this project were around the age of 9 weeks, considered full
grown adult at that time period. The overload surgery was performed on pairs of wild-
35
type and myostatin knockout mice in the same manner as previous published work (Dunn
et al., 1997, 1999). Briefly, the mice were anaesthetized with a cocktail of 1.6:1
Ketamine: Rompun the amount being ?µ?/lOOmg of body weight and allowed to resume
living for the duration of the overload period previously agreed upon. Muscles were
extracted on the day the overload period was complete, with the mice similarly
anaesthetized with the same dose of Ketamine: Rompun. After the plantaris was
extracted, the mice were euthanized using rapid cervical dislocation and the muscles were
weighed and stored in OCT compound frozen in chilled isopentene followed by rapid
submersion in liquid nitrogen. All muscles were stored at -86°C until experimental testing
was done on those muscles.
3.3: Semi Quantitative RT-PCR
RNA ^g) was reverse transcribed to produce cDNA of each sample to test gene
expression (Dunn et al., 1997). Negative RT tubes were prepared for each sample and
consisted of the same components of the positive RT reaction tubes with ultra-pure water
substituting for the addition of reverse transcriptase; this was used as an internal control
for the RT-PCR process. Briefly, each reaction tube consisted of 2µg of RNA, 2.5µ1 of
1 Opmol/µ? random primers (GE healthcare) working solution and ultra-pure water to
make equal volumes for each sample. The samples were heated for 10 minutes at 700C
and cooled on ice for 1 5 minutes to optimize primer binding. Reaction components
consisting of 4µ1 of 10X reaction buffer, 2µ1 of 1OmM dNTP mix (Invitrogen, CA), ?µ?
of RNAse inhibitor (Ambion, CA) and ?µ? of MMLV-RT (Ambion, CA) were added to
each reaction tube. Reaction tubes were incubated at 2O0C for 1 5 minutes, 37°C for 60
minutes and finally 65°C for 10 minutes to obtain cDNA. The cDNA obtained after RT
was used for semi quantitative PCR analysis for the various targets via use of specific
primer sets. Cycling conditions consisting of an initial denaruration step at 94°C and
depending on the target, between 30 to 40 cycles of 1 minute at 94°C, 1 minute at the
TAnneaiing, 1 minute at 72°C followed by a termination step at 72°C for 10 minutes. Each
PCR reaction tube contained 5µ1 of KCl PCR buffer (Fermantas), 2.5µ1 of
MgCl2(Fermantas) , 2µ1 of 2.5mM dNTPs, 5µ1 of each ?µ? forward and reverse primer,
0.5µ1 of Taq polymerase (Fermantas) and 2.5µ1 of cDNA made up to a total volume of






28S 55°C 142 F5'-TTGTTGCCATGGTAATCCTGCTCAGTACG-'3
R5'-TCTGACTTAGAGGCGTTCAGTCATAATCCC-'3
Atrogin-1 600C 138 F 5' -GCTTGTGCGATGTTACCCAAGAA-' 3
R 5'-GAAAGTGAGACGGAGCAGCTCT-'3
CnA 53°C 215 F 5'-CGATTCTCCGACAGGAAAAA-'3
R 5'-AAGGCCCACAAATACAGCAC-'3
BDNF 600C 486 F 5'-CTGGCTGACACTTTT-'3
R5*-AGTAAGGGCCCGAACATACGATTGG-'3
Follistatin 53°C 420 F 5'-CCTACTGTGTGACCTGTAATC-'3
R 5'-CTCCTCTTCCTCCGTTTCTTC-'3
Myostatin 600C 495 F5'-GACGATTATCACGCTACCACGGAAAC-'3
R5'-CATCGCAGTCAAGCCCAAAGTCTCTC-'3
Pax- 7 58°C 223 F 5'-GTAAGCAGGCAGGAGCTAAC-'3
R 5'-GGTTCATGAAGCTGTCAGAG-'3
Myogenin 58°C 392 F 5'-AGTGAATGCAACTCCCACAGC-'3
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R 5'- TCAGAAGAGGATGCTCTCTGC-' 3
3.4: Ribonucleic Acid (RNA) Extraction
Total RNA was extracted from plantaris muscle using a phenol-chloroform
extraction whereby two phases were formed, organic and aqueous layers, with RNA
remaining in the aqueous layer, and after centrifugation, the resulting pellet is
resuspended in ultra-pure water. Briefly, tissue samples were weighed and homogenized
with a hand-held Tissue Tearor (Biospec Products Ine, OK) for 30 seconds in lml/100mg
of tissue of a solution comprising 4M Guanidium thiocyanate (Sigma-Aldrich, MO),
25mM Sodium Citrate (Sigma-Aldrich, MO), 0.5% w/v N-laurylsarcosine (Sigma-
Aldrich, MO) and 0.1 M ß-Mercaptoethanol (Sigma-Aldrich, MO).Then 1:10 v/v of 2M
Sodium Acetate (Sigma-Aldrich, MO) was added after homogenization to neutralize the
negative charge of the RNA. This is followed by the addition of 1 : 1 v/v of phenol and
1 :5 v/v of chloroform, followed by vortexing and incubation on ice for 15 minutes.
Centrifugation of homogenates resulted in phase separation; the aqueous upper phase was
transferred to a fresh microfuge tube and 2:1 v/v of 99% v/v ethanol added. The contents
were vortexed, centrifuged and then the resulting pellet was re-suspended in 70% v/v
ethanol to remove excess salt. A final centrifugation was done to pellet the RNA. Lastly,
the pellet was air-dried for approximately and hour and then re-suspended in ultra-pure
water. RNA/DNA ratio and RNA concentration is determined using a spectrophotometer
(Eppendorff Biophotometer, Gernamy).
3.5: Cryosectioning and Immunohistological Experiments
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For all immunostaining procedures, the whole muscle was placed on cardboard
and the distal, mid-belly and proximal ends marked on the cardboard after extraction
from mice. The muscle was then evenly coated with Optimal Cooling Temperature
(OCT) mounting medium (Sakura Finetek USA Ine, CA) and placed in a pool of
isopentane pre-cooled in liquid nitrogen. The cardboard with mounted frozen muscle was
than stored in the larger liquid nitrogen dewer awaiting transfer to a -860C ultra-freezer
for long term storage. All cyrosectioning was done using a Leica cryostat (CM 3050 S
model, Leica Microsystems, Heidelberger, Germany) cooled to -23°C and set to a
thickness of 1 ?µ??. Serial sections were mounted on all slides, and control muscles as
well as treated muscle tissue sections were always mounted on the same slide to
accurately compare different conditions and eliminate any irregularities between slide
treatments. The method was adapted from previous Michel procedures (Dunn et al.,
1997).
Briefly, midbelly cryosections of plantaris hind-limb muscles were circled with a
hydrophobic PAP pen and blocked in 200µ1 ofblocking solution consisting of 5% w/v
Goat Serum (Sigma-Aldrich, MO) in 0.5% w/v Bovine Serum Albumin (BSA) (Sigma-
Aldrich, MO) for 30 minutes. They were then stained for the various MyHC isoforms
using 250µ1 of primary antibody developed against MyHC types I (A4.840), IIa (SC-71),
Hx (6Hl), IIb (BF-F3), Embryonic I (F 1.652), Embryonic II (47A) and Neonatal
isoforms (N2.261) (Developmental Studies Hybridoma Bank, University of Iowa, Iowa)
in 0.5% w/v BSA overnight at 4°C. Three washes in 250µ1 of IX Phosphate Buffered
Saline (PBS) were done for 10 minutes each before addition of the 250µ1 of secondary
antibody prepared in 0.5% BSA, consisting of either IgG-Horse Radish Peroxidase
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(HRP) or IgM-HRP (Sigma-Aldrich, MO) as required by the primary antibody make-up.
After incubation in secondary antibody for 2 hours, three washes were done using 250µ1
of IX PBS for 10 minutes each. Detection was accomplished using a horse-radish
peroxidase substrate, 3-3'-Diaminutesobenzidine [DAB] (Pierce Biotechnology Ine, IL)
in hydrogen peroxide (H2O2) (ACP, QC) in a coplin jar; air-drying of the slides, and
mounting in glycerin jelly was done as a final step.
3.6: Protein Extraction and Western Blotting
Plantaris muscle samples were homogenized on ice using a hand-held Tissue
Tearor (Biospec Products Ine, OK) in ?µ?/mg of IX RIPA buffer consisting of ???µ? of
each of 1OX PBS and 5% w/v Sodium Deoxycholate, 1OuI of each of Igepal (Sigma-
Aldrich, MO), 10% w/v SDS, IM Sodium Fluoride (Sigma-Aldrich, MO), lmg/ml
Aprotinin (Sigma-Aldrich, MO), lmg/ml Leupeptin (Sigma-Aldrich, MO), 10OmM
Phenylmethanesulphonylfluoride (PMSF) (Sigma-Aldrich, MO), and 5µ1 of 0.2M
Sodium Orthovanadate (Sigma-Aldrich, MO) filled to 1ml using autoclaved water.
Homogenates were left to incubate on ice for 45 minutes in the RIPA buffer.
Centrifugation at 1 5000 ? g for 20 minutes followed in a centrifuge pre-cooled to 4°C.
The supernatant was then transferred to a clean 1 .6ml closed cap vial, and a second round
of centrifugation was performed. The final supernatant is transferred to a clean 1.6ml vial
for storage at -86°C ultra-freezer.
Proteins in the amount of 50µg were loaded in 8 - 12% w/v SDS acrylamide gels
prepared as per the SDS-PAGE Bio-RAD Protocol (Bio-Rad Laboratories Ine, CA) and
electrophoresed at 120V through the stacking gel and 120V through the separating gel.
40
The separating gel consisted of 2.5ml of Tris buffer at pH 8.8, ???µ? of 10% w/v SDS,
30% acrylamide solution and autoclaved water amounts that depended on the percentage
of gels. The stacking gel consisted of 1.25ml of Tris buffer at pH 6.8, 50µ1 of 10% w/v
SDS, 3.0 ml of autoclaved water and 0.65ml of 30% acrylamide solution. Blotting of the
proteins onto a PVDF membrane (Amersham Biosciences, UK) was done by initially
soaking the membrane in 100% methanol for 10 seconds, followed by a wash in distilled
water for three minutes and incubation in transfer buffer. The filter paper and sponges
were also incubated in transfer buffer. Transfers were done for 1 hour at 100V.
Membranes are first stained with Ponceau S solution to verify the transfer was successful.
The Ponceau S (Sigma-Aldrich, MO) is then washed off using 0.1% Tween-Tris Buffered
Saline buffer (T-TBS), and the membrane is then ready for specific protein probing.
Membranes were initially blocked for one hour in the proper blocking solution, and then
membranes were incubated with primary antibody overnight on a shaker at 4"C.
Membranes were then washed 3x 10 minutes with T-TBS, before incubation with a
secondary antibody. Membranes were again washed 3x 10 minutes with T-TBS prior to
incubation with developing solution. Protein blots were quantified using alpha-Innotech
imaging software and analyzed as the integral of band width and intensity
3.7: Statistics
Statistical analysis of data comprised of 1 -way ANOVAs were performed for the
PCR experiments for the overload time course samples. Student T-tests were performed
for all other experiments involving overload and calcineurin pathway PCR analysis.




4.1: Identification and Characterization of the Myostatin Knockout Model
Myostatin knockout mice have distinct genotypic and phenotypic differences from
the wild-type mice used in the study. To verify that the mice used were in fact null for
myostatin, several tests were used. Figure 4.1 illustrates some of the characteristics
utilized to verify whether the generated mice were in fact null for myostatin. Figure 4.1 .A
depicts the map of where the neomycin cassette, the homologous construct introduced, is
placed within the myostatin gene thus disrupting the nucleotide sequence causing
myostatin to be either untranslated to its polypeptide sequence or for myostatin protein to
be degraded at once after translation because of the improper folding caused by the
introduction of the cassette. To verify that the mice that we generated did have the
inserted neomycin cassette, genotyping primers designed to span the sequence
encompassing the cassette were used to perform PCR to analyze whether the mouse had
the cassette or not, with the bands showing only the larger size PCR product indicating
that the mouse had the inserted cassette disrupting myostatin, as seen in Figure 4. 1 .B. The
second step in the verification process was testing for the presence of myostatin mRNA
transcripts. Semi-quantitative PCR using primers designed to amplify a section of the C-
terminal end of the myostatin sequence produced either a band of 495 base pairs in the
wild-type mouse, or an absence of this band in myostatin knockout mice, seen in Figure
4. 1 .C. This was used to confirm that the myostatin knockout mice were in fact missing
the mRNA for the active protein. To further support the absence of mRNA from the
Mstn-/- samples, an additional PCR experiment was performed, with increasing number
of cycles for the Mstn-/- samples. As seen in Figure 4.1.D, there were never any observed
bands in the knockout samples.
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Figure 4.1 : Identification of Myostatin Knockout Model A) The myostatin knockout
gene has a neomycin cassette inserted to disrupt its transcription (McPherron et al, 1997);
B) Representative image for genotyping from mouse tail clippings using primers that
recognize DNA portions specific for the Mstn+/+ and Mstn-/- homozygotes or both
portions representing heterozygote mice; C) Representative image of PCR product from
Mstn mRNA on EtBr stained agarose gel, 28S used as a loading control; D) Mstn PCR
product on EtBr stained agarose gels with increased cycle number for the Mstn-/- samples
to verify lack of PCR product
Figure 4.2 displays phenotypic changes observed in Mstn-/- mice to validate the
effectiveness of the knockout condition. One of the phenotypic data sets is absolute wet
weight of the muscles extracted, shown in Figure 4.2.A, which is a primary
characterization technique since myostatin knockout mice have muscles that are on
average larger than wild-type mice. To illustrate that more clearly, as in Figure 4.2.B, we
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used a measurement called relative muscle mass, which includes a correction for the body
weight of the mouse, as it relates to muscle weights. By doing so, we could see more
clearly that myostatin knockout tissues were larger, with ranges from 20% increases for
the soleus muscles, up to 60% increases for muscles like the gastrocnemius and tibialis
anterior. In Figure 4.2.C we see an H&E tissue stain for the plantaris muscles from
Mstn+/+ and Mstn-/- mice. It illustrates that myostatin knockout mice had muscles that
are larger in diameter than the wild-type counterparts. Considering that our functional
overload technique is used on plantaris muscles, further analysis for characterization was
performed on that specific tissue. Figure 4.2.D-F shows our quantified data for some of
the categories that were studied more closely in our overload experimental samples sets.
We measured the overall midbelly area from both wild-type and knockout mice, and the
results showed that the knockout midbelly is approximately double the size of the wild-
type (Fig 4.2.D). This doubling effect was attributed to two separate factors, namely the
mean myofibre cross sectional area, seen in Figure 4.2.E, and mean number of myofibres,
seen in Figure 4.2.F. Both overall size of the myofibres and their numbers were
approximately 50% greater in Mstn-/- plantaris as compared to Mstn +/+ tissue. In Figure
4.2.G we used a different way of analyzing myofibre size to illustrate how the Mstn-/-
muscle did exhibit larger fibres than wild-type. All these techniques were used in the
study to verify and correctly characterize that the mice used for the study were in fact
wild-types or myostatin knockouts.
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Figure 4.2: Phenotype Characterization of Muscles from Mstn-/- Mice A) Absolute
mass of muscle extracted from mouse calf; B) Relative Muscle mass to Body weight
graph; C) Haematoxylin and Eosin stain for Plantaris midbelly cross-sections from
Mstn+/+ or Mstn-/- mice, Bar scale= ???µ?t?; D) Mean Plantaris Midbelly cross-sectional
area; E) Mean Myofibre cross-sectional area; F) Mean myofibre number comparing
Mstn+/+ to Mstn-/- plantarii. G) Myofibre Size distribution comparing Mstn+/+ to Mstn-
/- plantaris muscle; * indicates p<0.05 relative to wild-type group
4.2: Plantaris Muscle Response to Functional Overload
One of the preliminary tests performed after harvesting all of the overloaded
plantaris muscles from the various time course points used for the study was testing the
mRNA expression of myostatin in the wild-type tissues only (since the knockouts do not
express the mRNA, as seen in Figure 4. 1 .C), to verify that our overload procedure did in
fact properly work. In Figure 4.3 we show that myostatin is significantly reduced to
approximately one fifth of the original quantity in all overload time course periods, which
was consistent with what was previously published regarding the overload protocol
(Dunn et al., 1999). This allowed us to continue our experimental analysis of all muscles
with the knowledge that the overload procedure was successful from the onset.
Figure 4 is a summary of the overall quantitative measurements analyzed from the
overloaded piantarli used in the study. Figure 4.4.A shows the relative weight of
overloaded piantarli harvested for the study. The graph shows that while the non-
overloaded sample was noted to be significantly different comparing wild-type to
knockout muscle, the significance was lost within all the other overload time points,
which hinted towards having differential muscle growth paces between wild-type and
knockout tissue. Figure 4.4.B represents images taken for some of the muscles extracted
for the study, the purpose being to have an estimate of the overall midbelly area of these
muscles from wild-type and myostatin knockout mice over the time course of the study.
Figure 4.4.C shows the mean cross sectional area from all myofibres analyzed in the
study, with the standard error bars indicated. This was a method used to quantify
hypertrophy due to the overloading. The hypothesis was with overloading, the average
cross sectional area of myofibres would increase in both wild-type and knockout, with the
knockout maybe showing greater hypertrophic potential than the wild-type. This was not
reflected in the results, which showed a tendency in the overall wild-type fibres to
undergo hypertrophy more than the knockout counterparts. This is interesting because it
suggests an underlying difference in response between wild-type and myostatin knockout
muscle, which was further investigated further. In figure 4.4.D we showed the overall
midbelly area from all the muscles for the study. This measurement was expected to be
similar in trend (upregulation) in both the wild-type and myostatin knockout mice.
Interestingly, after six weeks of overload, our piantarli from wild-type mice showed an
overall midbelly area very close in average to the myostatin knockout tissue. The last
graph, Figure 4.4.E, shows the mean fibre number in midbelly, calculated by dividing the
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overall average midbelly area by the average size of the myofibres. The goal was to try to
verify if the knockout muscle had more myofibres on average as compared to the wild-
type counterparts, a tendency that was confirmed in the non-overload muscle, but in the
overloaded muscle samples we had analyzed this trend was not fully apparent. However
it is not hard to predict that if more sampling is done that the trend showing more fibres
in the myostatin knockout muscle is indeed true, since it would account for the overall


















Figure 4.3: Myostatin mRNA Expression in Mstn+/+ plantaris of mice exposed to
Functional Overload. A) Representative image of Mstn mRNA on an EtBr stained
agarose gel across the various overload periods, 28S used as a loading control; B) Bar
graph quantification ofmRNA expression relative to 28S. * indicates significance within
p<0.05 from the non-OV level; ntc= control sample with no cDNA loaded; N=2 per
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Figure 4.4: Quantitative measurements for Plantaris in Response to Functional
Overload. A) Plantaris to Body weight ratio comparing Mstn+/+ Mstn-/- across different
overload periods; B) Representative images from sections of plantaris midbellies
analyzed, Bar scale= 1 ??µ??; C) Mean myofibre cross sectional area comparing Mstn+/+
Mstn-/- across different overload periods; D) Mean Midbelly Area comparing Mstn+/+
Mstn-/- across different overload periods; E) Mean myofibre number in midbellies
comparing Mstn+/+ Mstn-/- across different overload periods. * indicates p<0.05 relating
to the wild-type measurements; N=3 for the Non-OV samples, N=2 for OV time course
samples
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4.3: Myofibre Size and Fibre-Type Proportions Response to Functional Overload
Figure 4.5 lends more evidence to what was previously seen as a difference in
hypertrophy response between the wild-type and myostatin knockout piantarli tested. We
measured the increase of myofibre cross sectional area of the different MyHC isoform
expressing fibres. In the non-overloaded tissue, seen in Figure 4.5.A, all myofibre types
showed a tendency to be smaller than the knockout myofibres, by an average measure of
approximately 5-10%, not enough to be significant with our limited number of samples
tested, but enough to register a tendency that could be significant if more samples are
tested. After only three days of overload, a marginal change was registered in terms of
overall myofibre size, (Figure 4.5.B), which is understandable given the knowledge that it
takes weeks for muscle proteins to be synthesized. The results showed that over longer
periods of overload, the hypertrophy of all myofibre types was more evident in wild-type
piantarli tested as opposed to the knockout muscles, as seen in Figures 4.5.C and 4.5.D.
After 6 weeks of overload, the tendency was shifted towards showing bigger CSA
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Figure 4.5: Muscle Fibre Size Response to Functional Overload. Myofibre Cross
sectional area sizing according to Myosin Heavy Chain Isoform type expressed, A) Non-
OV CSA; B) 3day-0V CSA; C) 2wk-OV CSA; D) 6wk-OV CS; N=3 for the Non-OV
samples, N=2 for the OV time course samples
Figure 4.6.A through 6.D illustrate that MyHC isoform specific myofibre
composition within the muscle changes upon overloading, and the differences were more
evident in the wild-type than the knockout muscle. Again due to the small sample size
analyzed, the tendencies did not reach statistical significance, but showed a trend that is
interesting. The trend was that the wild-type muscle seems to be more capable of fibre-
type switching towards the more energy-efficient, oxidative myosin isoforms, than the
myostatin knockout fibres. The most evident difference was seen in the complete lack of
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the slowest fibre-types (MyHC I, and MyHC I/IIA) in the knockouts, while in the wild-
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Figure 4.6: MyHC Fibre-Type Proportions Response to Functional Overload.
Myofibre Expression Proportions according to Myosin Heavy Chain Isoform type
expressed, A) Non-OV CSA; B) 3day-OV CSA; C) 2wk-OV CSA; D) 6wk-OV CS; N=3
for the Non-OV samples, N=2 for the OV time course samples
4.4: mRNA Transcript Expression of Target Genes in Response to Overload
In an effort to explain the observed differences in response between wild-type
muscle and myostatin knockout muscle, we tested overloaded tissue for some well known
factors induced in muscle growth. Using the RT-PCR technique, (Figure 4.7.A), we
measured the mRNA transcript levels of these different targets to try to pinpoint what are
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the targets that respond differently in wild-type muscle as compared to knockout muscle.
Figures 4.7.B-E represents histograms showing the relative expression levels of the
different targets tested in this project. Atrogin-1 did not show any difference between
Mstn+/+ and Mstn-/- animals in reacting to overloading stimulus, with both sample
groups showing a similar decrease as overloading is extended. The same response was
seen with the expression Calcineurin A i.e., no difference between Mstn+/+ and Mstn-/-
mice, but a similar decrease in both over extended overloading periods. Brain-derived
neurotrophic factor (BDNF) expression initially was measured to be different between
Mstn+/+ and Mstn-/-, with an increase of BDNF showing in the knockout muscle relative
to its wild-type counterpart. However, with overloading, both Mstn+/+ and Mstn-/- mice
showed similar decreases in expression, negating the original discrepancy seen in the
non-overloaded samples. Myogenin and Follistatin were the only targets tested that
showed differential expression patterns in wild-type and knockout muscle. Myogenin
mRNA levels gradually increased during overload, with a tendency for the increase to be
more prominent in the knockout muscle as opposed to the wild-type muscle. Follistatin
expression dramatically increased in the wild-type group after 3 days of overload and
stayed higher than the control group throughout the other overload time points, while the
knockout registered only a slight increase that was similar across all time points, much
unlike the follistatin expression profile. These findings lent evidence to the assumption
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Figure 4.7: mRNA Expression of Target Genes in Response to Functional Overload.
A) Representative images of mRNA on EtBr stained agarose gels across the various
overload periods for: Follistatin (Fstn), Calcineurin A (CnA), Atrogin-1 (Atgn),
Myogenin (Mgn), Brain-derived neurotrophic Factor (BDNF), 28S used as a loading
control; B-F) B) Bar graph quantification of mRNA expression. * p<0.05 from the Non-
OV Mstn+/+ expression levels, ** p<0.05 from the 3day-OV Mstn+/+ expression levels,
# p<0.05 from the Non-OV Mstn-/- expression levels; ## p<0.05 from the 3day-OV
Mstn-/- expression levels; T p<0.05 between the paired bars. N=2 per group, preliminary
data run once in duplicate
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4.5: Protein Expression Response to Functional Overloading
The western blot in Figure 4.8, for protein extracted from the same piantarli that
were originally cut and stained for MyHC isoform IHC (n=2 for each time point), and
probed for Pax7 protein. The resulting histogram indicated a similar pattern to what
follistatin exhibited in mRNA transcript analysis; that being a marked increase in wild-
type three day overloaded muscle, then a gradual reduction over the following two time
points. The only difference between Mstn+/+ and Mstn-/-, muscle was seen in the three
day overloaded muscle, which indicated a fast response to functional overloading early in
the process, a response that is evidently different in knockout from wild-type muscle.
Early testing with anti-myogenin antibody on wild-type and myostatin knockout
muscle showed, a significant difference in expression of myogenin between the two
groups (n=2), namely a three-fold increase in myogenin protein expression in the
myostatin knockout plantaris as compared to the wild-type counterparts (in Figure 4.9).
The difference was more pronounced at the protein level than the observed expression at
the mRNA level that was measured earlier (Figure 7.E).
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Figure 4.8: Plantaris Pax7 Protein Expression in response to Functional Overload.
A) Representative protein western blot representing Pax7 expression across the various
overload periods, Ponceu S staining was used as a loading control; B) Bar graph
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Figure 4.9: Myogenin is differentially expressed in Non-Ov Mstn+/+ or Mstn-/-
Plantaris. A) Western blot membrane representing Mstn+/+ or Mstn-/- samples probed
with anti-myogenin antibody, a-tubulin was used as loading control; B) Bar graph
quantification of protein expression, indicates significance within p<0.05 from the
Mstn+/+ expression levels. N=2 per group, preliminary data performed once
4.6: Myostatin Levels in Transgenic Mice variants of Calcineurin Expression
By testing the mRNA transcript levels ofmyostatin in different transgenic mice
models that were engineered to overexpress or lack proteins known to be players in the
calcineurin pathway, we tried to shed light on any possible link between the hypertrophy
linked calcineurin pathway and the regulatory role of muscle growth dictated by
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myostatin. Results in Figure 4.10 showed that mice overexpressing CamBP (n=3) showed
a decrease in the myostatin mRNA transcript, while no significant change was observed
for the PV-HA transgenic mice (n=3), both compared to CD-I wild-type mice (n=3), the
mouse strain used for generating these transgenic lines. Also tested were the NFATc2
knockout mice (n=3), NFAT being a downstream signalling propagator of calcineurin,
and the results showed a marked increase in the myostatin mRNA transcript as compared
to the wild-type Balb/c wild-type strain (n=3) that was used to generate this NAFTc2-/-
mouse strain. This is interesting because it gives us evidence that inhibiting a direct signal













Figure 4.10: Myostatin mRNA expression in muscles of TG mouse variants of
Calcineurin Expression. A) Representative image of Mstn mRNA run on EtBr stained
agarose gel across the various Transgenic mice models, 28S was used as a loading
control; B) Bar graph quantification of mRNA expression, indicates significance within





We set out to study the effects of myostatin in muscles that are, due to increased
load and neural activation, in the process of growing using a process known as plantaris
functional overloading. It is achieved by the surgical ablation of the synergist muscles of
the plantaris, namely the gastrocnemius and soleus leaving the plantaris with the sole task
of performing ankle plantar flexion. By analyzing wild-type and myostatin null
genetically engineered mice, we set out to understand the role that myostatin plays in
overload-induced muscle growth, specifically how myostatin affects the hypertrophic and
hyperplasic signalling pathways implemented by muscles during the growth process. We
hypothesized that the hypertrophic and hyperplasic growth pathways will be more
potentiated in myostatin null mice as compared to their wild-type counterparts. Our
results suggest that myostatin is involved in inhibiting the hyperplasic growth signalling
pathway in a higher capacity than the hypertrophic pathway leading to a differential
response to functional overload between myostatin null mice and wild-type mice.
We performed several initial identification and characterization experiments to
assess the knockout mouse model that was generously provided to us by Dr. Se-Jin Lee's
John Hopkins' lab. As shown in Figures 1 and 2, our resulting data analysis was similar
to what other groups have shown when using the same myostatin knockout model and the
original wild-type strain C57BL. Our data were consistent with what Dr. Se-Jin Lee (Lee,
2007) and Dr. Patel (Matsakas et al., 2009) have published earlier, with Dr. Lee reporting
approximately 50% increase in absolute muscle mass of the gastrocnemius muscle for the
myostatin knockout mice. As well, in that study, Dr. Lee reports that Mstn-/-
plantaris/gastrocnemius muscles show a relative increase in fibre number of approx 50%
and an increase of approx 40% in the cross-sectional area of fibres in these muscles.
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These data sets were collected from mice aged 10 weeks which is younger than our
testing age, which could explain why our results are slightly different than their reported
data. Dr. Patel reports an increase in muscle weight in the EDL and gastrocnemius
muscles after injecting wild-type mice with the inhibitory propeptide of myostatin loaded
vectors to overexpress that protein to counter the effects of myostatin in these muscles.
This method, however, only produced a 20% increase in overall muscle weight, with its
inherent inability to completely neutralize myostatin' s presence in muscles. These studies
allow us to compare our results regarding muscle overload to that of what others have
studied even when their methods for experimentally altering the muscles are different
from our technique.
Our results showed that myostatin does play an inhibiting a role in regulating
muscle growth, and more specifically it seems to be controlling the satellite cell
participation in muscle growth as opposed to regulating the existing mature myofibres
present prior to the induction of exercise stimulus by means of functional overload. What
this means is that wild-type muscles, with their native expression of myostatin, respond
to functional overload by activating hypertrophy-related pathways, while myostatin null
muscles respond by activating less the hypertrophy and more the hyperplasia related
pathways for muscle growth. As seen in Figure 4, both wild-type and myostatin knockout
muscle midbellies appeared to grow to the same extent. However the overall composition
of the muscles differed, with a tendency for wild-type muscle to show bigger mature
myofibres, while the knockout model showed a tendency for increased number of
myofibres in the midbelly.
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By analyzing the mean cross sectional area of the different myofibre types, as
seen in Figure 5, the results showed a tendency for wild-type myofibres to respond by
increasing their CSA to a greater extent than what Mstn-/- myofibres were able to
accomplish. The results from this study show that the overall increase for the wild-type
myofibre CSA is approximately 65% while previous results from Dr. Michel's (Dunn et
al., 1999) group report a doubling effect from functional overloading of plantaris muscle.
Considering that our study was performed on a limited number óf mice, the results might
be underestimating the gap from hypertrophy in the wild-type muscle compared to the
knockout muscle. It is prudent to note that Mstn-/- myofibres at rest are known to be
overall larger than Mstn+/+ myofibres (Lee, 2007), as seen in Figure 2.D, but over the
time course studied, their size is eclipsed by the wild-type myofibres. This increase alone
would suggest that wild-type muscles would grow to be larger than myostatin knockout
tissue over the course of the overload period. However this was not observed, and is
explained by the greater hyperplasic response seen in knockout tissue as compared to
wild-type tissue. This increase is seen in Figure 4.E, where the mean number of
myofibres in the midbelly of plantaris muscle was calculated based on dividing the
midbelly overall area by the mean cross sectional are of the myofibres present in the
midbelly. While the tendency shows a slightly greater number of myofibres in the
midbelly ofknockouts, it did not reach statistical significance with the limited number of
samples. However, it is conceivable that with a larger pool of samples, the numbers
would reach significance, being larger in the knockout muscle compared to the wild-type
counterparts. As reported earlier, myostatin knockout mice have a greater number of
myofibres, approximately 50% more relative to wild-type muscle (Lee, 2007) before any
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experimental procedures are performed. Also it has been shown earlier by Dr.
Kambadur's group, by performing IF analysis on myoblasts and colocalizing myostatin to
the nuclei of these developing cells, that myostatin does inhibit satellite cell activation
(McCroskery et al., 2003) and comparing these to Mstn-/- samples that show a lack of
myostatin presence in these cells and an overall increase number of these myoblasts.
Taken together, published research establishes that in the absence of a myostatin
inhibitory role in muscles, satellite cell rate of proliferation is increased. Here we showed
that when Mstn-/- plantaris muscles are stimulated to grow, they had a tendency to up-
regulate the rate of satellite cell proliferation, inducing a hyperplasic growth response,
that is unmatched by the wild-type muscle stimulated in a similar fashion.
Another important parameter that we analyzed is the fibre-type proportion
changes that would occur over a prolonged overload period. Previous work done with
similar techniques reported that with overload, there would be a significant amount of
fibre-type remodelling that change towards expression of more oxidative (slow) MyHC
isoforms (Dunn et al., 1997, Dunn et al., 2001, Olsen et al., 2000, Pehme et al., 2004). In
Figure 6, the graphs show that the Mstn+/+ tissue did exhibit the normal shift of fibre-
type proportions towards the slow phenotype, while the Mstn-/- proportions did not show
the tendency to shift their fibre-type composition to any significant extent. This fact,
coupled with the knowledge that Mstn-/- muscles have a higher activation state for
glycolytic pathways (Steelman et al., 2006, Ilham et al., 2009), lends to the idea that
myostatin may control the expression of oxidative MyHC isoforms. In cases where it is
not present, the muscle tends to express only the energy inefficient, glycolytic fibre-types
(Handschin et al., 2007).
65
This is one of the significant findings of this project, namely the inability of Mstn-
/- muscle to express or remodel existing myofibres to more energy efficient MyHC
isoforms. This allowed us to explore in more detail what the function ofmyostatin is,
beyond the already understood role of regulating the size of muscles. Here we showed
that without myostatin's expression, muscle is at risk ofbecoming more energetically
inefficient by producing myofibres that are biochemically more taxing on the energy
expenditure of the body with their increased need for ATP when induced to grow. Also
knowing that MyHC isoforms that utilize glycolytic pathways for producing their energy
are also easily fatigued, and unable to perform their forceful contraction for a prolonged
period of time, this leads to muscles that lack great physical endurance.
In order to understand the signalling pathways that are altered differently in the
Mstn-/- model compared to the wild-type controls, we pursued looking at the expression
of mRNA from target genes that are known to be associated with muscle growth, and in
one case muscle atrophy. Specifically, we looked at follistatin (Lee, 2007), calcineurin A
(Dunn et al., 1999, 2001), atrogin-1 (Zhang et al., 2007), myogenin (Yafe et al., 2008),
and brain-derived neurotrophic factor (Mousavi et al., 2006). These preliminary sets of
experiments were done using polymerase chain reaction techniques to assess the levels in
which certain genes were transcribed. Comparing Mstn+/+ and Mstn-/- plantaris mRNA
across all of the time points analyzed provided an understanding of the expression
profiles of these chosen targets. Figure 7.A represents the images acquired after
performing polymerase chain reaction experiments, with all graphs representing the level
of PCR product relative to the expression of controls.
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Our preliminary results showed that out of the five tested gene targets, both
calcineurin and atrogin-1 reacted in similar fashion in both Mstn+/+ and Mstn-/- across
all the overload time points, as seen in Figures 7. C-D. In both instances the mRNA
transcript levels decreased after 2 weeks, and maintained that lowered expression level up
to the 6 week overload period. Atrogin-1 is an agent of protein degradation, an ubiquitin
ligase that marks proteins for proteolysis (Zhang et al., 2007) making it a prime target for
downregulation during muscle growth phase. Its expression was decreased after
prolonged overload which can easily be explained by the fact that the overload process
increases anabolic processes and decreases catabolic/proteolytic pathways. The graph
indicates that the decrease of calcineurin and atrogin-1 is similar in both wild-type and
myostatin knockout muscle which indicates that myostatin is not acting on these two
proteins directly in our growth stimulus procedure. The fact that atrogin-1 mRNA acted
similarly between wild-type and myostatin knockout tissue has been reported before, at
least for control groups, by Dr. Thissen's group (Gilson et al., 2007), specifically, they
reported no significant difference in mRNA levels between the two groups. Calcineurin
expression mirrored the trend seen with atrogin-1, namely the expression is decreased
significantly after 2 weeks and maintained at the same decreased level up to the 6 week
overload period.
With the knowledge that calcineurin is part of the signalling pathway that
increases the expression of slow MyHC isoform fibre-types, with published results
showing a 2-fold increase in MyHC I in the plantaris after 4 weeks of overload (Olsen et
al, 2000, Dunn et al., 2001), it is difficult to explain why the mRNA transcript of this
gene has decreased over the prolonged overload period. One explanation might be that
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the protein expression levels might not mirror the mRNA transcript levels, which is not
uncommon in these kinds of studies. Another explanation might be that other signalling
pathways that induce myofibre remodelling are more affected by the overload procedure
than the calcineurin pathway, studies by Dr. Glass's group (Bodine et al., 2001) and Dr.
Powers' s group (Sugiura et al., 2005), point to the Akt pathway as a major role player in
remodelling within muscle in response to functional overload stimuli. We did show that
slower MyHC-expressing myofibres are produced with prolonged overload, as in Figure
6.C-D where the proportion of MyHC I and I/IIA are seen in greater frequency after 2-6
weeks as compared to the control tissue. It is worthwhile to note that since Mstn-/-
muscle is shifted towards expressing more glycolytic myosin heavy chain isoforms, it is
then understandable that the calcineurin expression is decreased in those muscles, since it
does not seem that these knockout muscles are capable of producing many oxidative
(slow) myofibres from the initial stages, a finding supported by Dr. Cessar-Malek's group
(Ilham et al., 2009). This group use microarray bioinformatic analysis of samples taken
from Mstn-/- and wild-type counterparts, and concluded that the myostatin knockout
mouse model shows a significant downregulation of gene expression related to oxidative
myofibres and an upregulation for the glycolytic pathways in those samples. In our study
we analyzed the expression of MyHC isoforms by immunohistochemical staining and our
results showed a lack of fast-to-slow fibre-type switching in the Mstn-/- piantarli tested
which is in line with what is expected of the knockout model.
Since both atrogin-1 and calcineurin have responded in a similar fashion when
comparing Mstn+/+ and Mstn-/- overloaded muscles, we decided to probe for more
targets that would show a difference in expression profiles. This would shed light on the
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apparent variation in reacting to functional overload that led the wild-type tissue to
express more of a hypertrophic growth response while the myostatin null tissue expresses
more of a hyperplasic response. Figure 7.B shows the graph resulting from preliminary
measurements of follistatin mRNA transcript levels across the various overload periods
tested. In this graph the results showed a marked difference between wild-type and
myostatin knockout tissue. After only three days of overload, the follistatin expression in
the wild-type has increased by approximately 4-fold as compared to the non-overloaded
controls, while the Mstn-/- levels do not change. This difference is however temporary,
since at all subsequent time points, the levels returned to approximately non-OV
expression patterns in both types of tissue. The difference seen after three days of
overload in the wild-type tissue allowed us to speculate that follistatin, the competitive
inhibitor of myostatin, was preferentially upregulated in wild-type tissue to accomplish
multiple roles. One role being to neutralize the myostatin present in the muscles of wild-
type tissue (allowing the wild-type tissue to grow). Another role suggests that follistatin
is involved in activating hypertrophy-promoting signalling pathways, as reported by Dr.
Kaspar in his study of follistatin injection into wild-type mice (Haidet et al., 2008). In this
study, they use a method of injecting the follistatin gene in mice and analyzing muscle
weight as well as myofibre number. Their result indicate that increased follistatin within
muscles leads to increased weight of those muscles accompanied by decreased myofibre
number, a clear indicator for hypertrophy over hyperplasia. In our case, the lack of
upregulation of follistatin in Mstn-/- tissue does explain the inability for the myofibres of
myostatin null mice to match the hypertrophic increase seen in the wild-type tissue.
Follistatin is an agent of hypertrophic growth response of muscle (Haidet et al.,
2008), and knowing that it is, in fact, differentially regulated between wild-type and
myostatin knockout tissue, we proceeded to test for a gene implicated in hyperplasic
growth response in skeletal muscle in order to verify that the myostatin knockout tissue
does employ this pathway more heavily than in the wild-type tissue. One of the genes
involved in the hyperplasia pathway is myogenin, a muscle regulatory factor that is
known to be involved with satellite cell activity, specifically its increased expression
during the proliferation stage of satellite cells and locking the myoblasts into path of
maturation (Kuang et al„ 2007, Le Grand et al., 2007). Figure 7.E presents the graph of
the preliminary expression profile of myogenin protein, and in this graph we did in fact
register a statistically significant difference between wild-type and myostatin knockout
tissue. Myogenin seems to be preferentially upregulated in the Mstn-/- tissue more so
than the wild-type, with the peak of its expression coming around the 2 week mark in our
study. This allowed us to conclude that satellite cell proliferation and maturation is more
evident in myostatin null tissue as compared to wild-type tissue, allowing us to verify that
myostatin is in fact an inhibitor to satellite cell activation and proliferation. Myostatin' s
involvement in satellite cell inhibition was mentioned earlier in and is supported by the
work of Dr. Kambadur (McCroskery et al., 2003). As further illustration that myogenin is
a key regulator in the hyperplasic growth response in muscle, Dr. Bodine's (Cohen et al.,
2007), and Dr. Goldman's (Macpherson et al., 2006) groups have shown that myogenin
has a role in stabilizing neuromuscular junction formation. They have identified that
myogenin promotes the clustering of acetylcholine receptors where the neuron forms a
synapse with the myofibre. This is linked to hyperplasia in the sense that newly formed
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myofíbres would require formation of neuromuscular junctions and, therefore, it would
be logical that myogenin can serve the dual role of signalling as a maturation agent for
satellite cells to form new myofíbres and as a neuromuscular junction formation agent.
One final gene target that was of interest to us is brain-derived neurotrophic factor
(BDNF). It is a stabilizer of synaptic connections between myofíbres and their motor
neurons (Mousavi et al., 2007). It is also expressed within satellite cells in the same
manner as Pax7 (Mousavi et al., 2007). This means it is implicated in maintaining the
present state of communication between motor neurons and the mature myofibre state
(Mousavi et al., 2007). With functional overload, the pre-existing state of motor neuron
connections and myofíbres would not be sufficient to the muscle because of the extensive
remodelling due to hypertrophy and hyperplasia. Therefore it is logical for BDNF
expression to be reduced, allowing a new state of neural branching and remodelling of
neuromuscular junctions to occur within the growing muscle. We tested the mRNA
transcript levels of BDNF, Figure 7.F, and our results showed that BDNF was
upregulated in the knockout muscle in a statistically significant manner. However after
overload, the levels in both wild-type and knockout mice are reduced significantly across
all overload time points. Put together, the mRNA transcript analysis lends support to the
hypothesis that myostatin is responsible for regulating pathways involved in activation of
satellite cells, and thus Mstn-/- tissue employs the hyperplasic growth pathway, rather
than the hypertrophy pathway, as a response to functional overload more readily than
wild-type tissue that has native myostatin levels inhibiting the activation of these
pathways.
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We pursued the analysis of Pax7 at the protein level in order to investigate
whether it is differentially regulated between wild-type and myostatin knockout tissue.
The reasoning behind this is that Pax7 is a well known quiescence marker of satellite
cells (Kuang et al., 2007, Seale et al., 2000, Le Grand et al., 2007), and its expression
level is used as a measuring parameter on whether satellite cells are being activated or
maintained quiescent. Our resulting preliminary western blot analysis, as seen in Figure
8, did not achieve statistical significance in any of the groups tested. However, a tendency
for Pax7 protein to be upregulated in the wild-type group after only 3 days of functional
overload was noted. This tendency might become significant if more samples are tested.
We thus speculate that Pax7 plays a role in inhibiting wild-type muscles from activating
the quiescent satellite cells, as would be supported by the findings of Dr. Olwin's group
(Olguin et al, 2004) as well as Dr. Kambadur's group (McFarlane et al., 2008). Both
studies performed immunofluorescence staining of satellite cells, specifically Pax7
protein, and concluded that when satellite cells are activated, Pax7 protein ceases to be
expressed in these cells. Taken together, the research states Pax7 is an inhibitor to
satellite cell activation and proliferation. Therefore, an initial increase in its protein level
would suggest the wild-type tissue is attempting to prevent the signalling propagation that
would lead to increased myofibre formation, and hence direct muscle growth towards
increasing the size of already available mature myofibres, causing myofibre hypertrophy.
Preliminary analysis was also performed on myogenin at the protein level, as it
was determined to be a key determinant showing the differential signalling pathways that
are employed by the muscle in response to overload when comparing Mstn+/+ and Mstn-
/- tissues. Figure 9 illustrates how in non-overload state, the myostatin knockout
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expressed myogenin at a 3-fold greater level than in wild-type plantaris muscle. This
replicated the trend seen at the mRNA transcript level seen in Figure 7.E, and therefore,
provides further evidence that myogenin is, in fact, differentially regulated between
Mstn+/+ and Mstn-/- tissue. Future experiments would have to analyze the myogenin
expression profile of both types of tissue across all the time points used in the overload
study, similar in fashion to what was done for Pax7 in Figure 8, in order to fully support
the findings at the mRNA transcript levels that indicated an increased upregulation of
myogenin in all overload time points as compared to their wild-type paired groups. This
will solidify the findings of the earlier results and it would implicate myogenin as a key
regulator of myofibre hyperplasia due to increased satellite cell proliferation and
maturation, leading to the observed increase in myofibre number noted.
Our analysis of all the results leads us to suggest that myostatin has an inhibitory
effect on the hyperplasic muscle growth response more profound than its effect on the
hypertrophic growth response. As mentioned earlier, the calcineurin pathway is an
established map for muscle hypertrophy response to functional overload (Dunn et al.,
1999, 2001), we set out to analyze the mRNA transcript levels ofmyostatin in several
transgenic mice models engineered to affect the calcineurin signalling pathway. It was
interesting to try to investigate whether transgenic mouse models engineered to have an
effect on the signal propagation involved in the calcineurin pathway would result in an
effect on the expression of myostatin, at least in the mRNA transcript level. One of the
threads of interest was based on previous research done by Dr. Pavlath's group, where
they show that the calcineurin-NFAT pathway was implicated in satellite cell activation
(Friday et al., 2001). In their published study, they use myotubes cultured cells and
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precursor cells (used as models for satellite cells in vivo) as samples that they treat with
activation or inhibitory agents on calcineurin, and they analyzed the mRNA levels of
Myf5, one of the myogenic regulator factors involved in satellite cell maturation and
differentiation (Friday et al., 2001). Their work indicates that inhibiting calcineurin
effectively inhibits the expression of Myf5 and thus they conclude that there is a link
between the calcineurin-NFAT pathway and satellite cell activation (Friday et al., 2001).
Therefore, we saw it as prudent to assess the levels of myostatin mRNA expressed in
some of the transgenic models available to us, namely the TnIs-PVHA mouse model, the
Tnls-CamBP mouse model and the NFATc2-/- mouse model, as well as the proper wild-
type mouse backgrounds to each model. The TnIs-PVHA model was designed previously
(Chin et al., 2003) to allow for slow myofibres to implement calcium oscillatory patterns
that mimic fast fibre states without leading to complete myofibre remodelling from slow
to fast. The Tnls-CamBP model was previously designed (Wang et al., 1995) to
overexpress the calmodulin binding protein (CamBP) protein, essentially lowering the
availability of Ca-Cam complex concentrations and hence the activation of calcineurin.
The CamBP gene was coupled to the TnIs promoter region allowing for increased
expression of CamBP within slow myofibres. The NFATc2-/- model was designed by
knocking out the functional NFATc2 protein by the introduction of a neomycin cassette
within the gene to cause the generation of a non-functioning transcript (Hodge et al.,
1 996). This is similar to the myostatin knockout model generation process done by Se-Jin
Lee (McPherron et al., 1997). Figure 10.A shows the resulting agarose gels of the PCR
performed on the various muscles to properly test myostatin mRNA expression. For
TnIs-PVHA and Tnls-CamBP mice, the soleus muscle was selected for testing because
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the designed transgenic model allows for overexpression of CamBP and PVHA in slow
fibres and not fast fibres, and soleus is composed of mostly slow, oxidative myofibres at
about 58% in proportion (Girgenrath et al., 2004). The PVHA genetic model is designed
to have an irregular calcium oscillatory rhythm within the myofibre, affecting the calcium
concentrations found in the cytoplasm of these fibres. This in effect lowers the
availability of calcium ions that would normally be able to bind to calmodulin forming
the Ca-Cam complex.
Decreasing the Ca-Cam concentration effectively lowers the activation of
calcineurin since the Ca-Cam complex is found upstream of calcium (Olsen et al., 2000).
Our results did not show a significant alteration of myostatin mRNA in this specific
model. This might indicate that the decrease of activated levels of calcineurin do not
necessarily have a direct effect on myostatin transcription levels. As for the Tnls-CamBP
model, which over expresses calmodulin-binding protein, our results show a decrease in
the myostatin mRNA transcript level that is approximately one half of the wild-type
levels. However, since CamBP, in effect, is expressed in the body to decrease the activity
of Ca-Cam complex, one would have assumed that it would ultimately have the same
effect on myostatin as in the TnIs-PVHA model, which is not the case. This could be
explained by noting that the TnIs-PVHA mice, which were studied by Dr. Michel's group
(Chin et al., 2003) did not show a tendency to remodel their soleus myofibres from slow
to fast, and therefore maintaining the same myofibre expression profile similar to CDl
wild-type mice can account for the non-significant change of myostatin mRNA
expression. Finally we tested NFATc2-/- tissue for the expression of myostatin. NFAT
isoforms are known to be downstream effectors of calcineurin, and their role in gene
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activation is extensively researched. Dr. Michel's group is actively studying the exact
role that knocking out NFAT isoforms plays in skeletal and cardiomyocyte hypertrophy.
Dr. De Windt's group's published a study showing in NFATc2-/- mice, cardiac
hypertrophy was fully attenuated (Bourajjaj et al., 2008). In our study, we analyzed the
expression of myostatin as a result of knocking out the c2 isoform ofNFAT. Our results
show that by removing the final link between the calcineurin pathway and its target
genes, the levels of myostatin mRNA transcripts are increased to 3-fold. This is a
significant alteration that lends support to the idea that calcineurin and myostatin
pathways are cross-linked and work in opposite fashions, therefore lending control
mechanisms that would keep both hypertrophic and anti -hypertrophic pathways in check.
In conclusion, our study showed that myostatin' s effect on growing muscle is
most apparent in attenuating the hyperplasic growth response in stimulated muscle, and
not the hypertrophic signalling pathway. By analyzing both physiological and molecular
parameters in functionally overloading plantaris muscles from wild -type and myostatin
knockout mice, we determined that the knockout muscles showed a tendency to increase
myofibre number as a response to growth stimuli, while wild-type muscle showed a
tendency to enlarge the pre-existing mature myofibres. This is the first in vivo study to





In order to verify the tendencies seen in this project, we have to increase the
number ofmice tested for each treatment group so that the measurements can be
statistically shown to be significant. Also, it is of importance to analyze the mRNA
expression levels using a technique that is more accurate than semi-quantitative PCR.
Therefore, it is planned to use real time PCR experiments to acquire a more accurate
assessment of the expression levels of our target genes of interest, as well as other targets
that also participate in hypertrophy and hyperplasia pathways. Hence targets such as
activin, activin IIB receptor, and smad2/smad3 are seen as future targets to assess in
relation to the hypertrophy pathway. As for the hyperplasia-related pathway, targets such
as MyoD, MRF4 and Myf5 are all interesting to analyze so that we can track the different
phases of satellite cell activation, to maturation.
Further experiments such as immuno-fluorescence detection of satellite cells in
the functionally overloaded plantaris tissues are also important to visually verify the
activation of satellite cells. Therefore, simultaneous staining of Mstn+/+ and Mstn-/-
tissue for satellite cell markers such as BrdU or m-cadherin are important, coupled with
staining for myogenin to assess the number of activated satellite cells.
Finally, in an attempt to investigate in more detail the association between
myostatin and the calcineurin pathway, it would be prudent to generate cross breeds of
myostatin knockout mice with transgentically modified mice overexpressing calcineurin,





Allen, D. L., Cleary A. S., Speaker K. J., Lindsay S. F., Uyenishi J., Reed J. M.,
Madden M. C, and Mehan R. S., 2008. Myostatin, activin receptor IIb, and
follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of
obese mice. Am JPhysiol Endocrinol Metab. Vol.294 p.E91 8-E927
Allen, D. L., and Unterman T. G., 2007. Regulation ofmyostatin expression and
myoblast differentiation by FoxO and SMAD transcription factors. Am JPhysiol Cell
Physiol. Vol.292 p. 188-1 99
Amirouche, A. D., Banzet S., Koulmann N., Bonnefoy R., Mouret C, Bigard X.,
Peinnequin A., and Freyssenet D., 2009, Down-Regulation of Akt/Mammalian Target
of Rapamycin Signaling Pathway in Response to Myostatin Overexpression in
Skeletal Muscle. Endocrinology. Vol.150 (1) p.286-294
Amthor, H., Otto A., Vulin A., Rochat A., Dumonceaux J., Garcia L., Mouisel E.,
Hourde C., Macharía R., Friedrichs M., Relaix F., Zammit P. S., Matsakas ?., Patel
K., and Partridge T., 2009. Muscle hypertrophy driven by myostatin blockade does
not require stem/precursor-cell activity, PNAS. Vol. 106 (18) p.7479-84
Amthor, H., Otto A., Macharía R., McKinnell L, and Patel K., 2006. Myostatin
Imposes Reversible Quiescence on Embryonic Muscle Precursors, Developmental
Dynamics. Vol. 235 p.672-680
Anderson, S. B., Goldberg A. L., and Whitman M., 2008. Identification of a Novel
Pool of Extracellular Pro-myostatin in Skeletal Muscle. Journal OfBiological
Chemistry. Vol. 283 p.7027-7035
Armand, A. S., Gaspera B. D., Launay T., Charbonnier F., Gallien C. L., and
Chanoine C, 2003. Expression and Neural Control of Follistatin Versus Myostatin
Genes During Regeneration of Mouse Soleus. Developmental Dynamics. Vol.227
p.256-265.
Atherton, P. J., Higginson J. M., Singh J. and Wackerhage H., 2004. Concentrations
of signal transduction proteins mediating exercise and insulin responses in rat
extensor digitorum longus and soleus muscles. Molecular and Cellular
Biochemistry..Vol. 261 p. 1 1 1-1 16
Baumann, A.P., Ibebunjo C, Grasser W.A., Paralkar V.M., 2003. Myostatin
expression in age and denervation induced skeletal muscle atrophy. JMusculoskel
Neuron Interact. Vol.3 (1) p.8-16
Bellinge, R. H. S., Liberies D., laschi S., O'Brien P. A. and Tay G. K., 2005.
Myostatin and its implications on animal breeding: a review. Animal Genetics. Vol.36
p. 1-6
80
Bodine, S. C, Stitt T. N., Gonzalez M., Kline W. O., Stover G. L., Bauerlein R.,
Zlotchenko E., Scrimgeour ?., Lawrence J. C, Glass D. J. and Yancopoulos G. D.,
2001 . Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and
can prevent muscle atrophy in vivo, Nature Cell Biology. Vol 3 p. 101 4-1 01 9
Bourajjaj, M., Armand A. S., Da Costa Martins P. A., Weijts B., Van der Nagel R.,
Heeneman S., H. Wehrens X., and De Windt L. J., 2008. NFATc2 Is a Necessary
Mediator of Calcineurin-dependent Hypertrophy and Heart Failure, Journal of
Biological Chemistiy. Vol 283, p. 22295-22303
Bradley, L. P., J. Yaworsky and F. S. Walsh; 2008. Myostatin as a therapeutic target
for musculoskeletal disease. Cellular and Molecular Life Sciences. Vol. 65 p.21 19-
2124
Carlson, C. J., Booth F. W., and Gordon S. E., 1999. Skeletal muscle myostatin
mRNA expression is fiber-type specific and increases during hindlimb unloading. Am
J Physiol Regulatory Integrative Comp Physiol. Vol.277 p.60 1-606
Chen, J. C, and Goldhamer D. J, 2003. Skeletal muscle stem cells, Reproductive
Biology and Endocrinology. Vol. 1 3 p. 1 01 -1 08
Chin, E. R., Grange, R. W., Viau, F., Simard, A. R., Humphries, C, Shelton, J.,
Bassel-Duby, R., Williams R. S., and Michel, R. N., 2003. Alterations in slow-twitch
muscle phenotype in transgenic mice overexpressing the Ca2+ buffering protein
parvalbumin, Journal ofPhysiology. Vol 547 p.649-663
Cohen, T. J., Waddell, D. S., Barrientes, T., Lu, Z., Feng, G., Cox, G. A., Bodine, S.
C, and Yao, T., 2007. The Histone Deacetylase HDAC4 Connects Neural Activity to
Muscle Transcriptional Reprogramming, Journal ofBiological Chemistry. Vol 282,
p. 33752-33759
Dasarathy, S., Milan D., Muc S. M., Kalhan S. C, and McCullough A. J., 2004.
Skeletal muscle atrophy is associated with an increased expression of myostatin and
impaired satellite cell function in the portacaval anastamosis rat, Am JPhysiol
Gastrointest Liver Physiol. Vol.287 p.l 124-1 130
Day, K., Paterson B., and Yablonka-Reuveni Z., 2009. A Distinct Profile of
Myogenic Regulatory Factor Detection Within Pax7 Cells at S Phase Supports a
Unique Role of Myf5 During Posthatch Chicken Myogenesis. Developmental
Dynamics. Vol. 238 pi 001-1 009
Drummond, M. J., Glynn E., Lujan H., Dicarlo S., and Rasmussen Blake., 2008. Gene
and protein expression associated with protein synthesis and breakdown in paraplegic
skeletal muscle. Nerve Muscle. Vol.37 p.505-513
81
Dunn, S., and Michel, R., 1997. Coordinated expression of myosin heavy chain
isoforms and metabolic enzymes within overloaded rat muscle fibers, American
Journal Physiology Cell Physiology. Vol 42 p37 1 -383
Dunn, S. E., Burns, J. L., and Michel, R. N., 1999. Calcineurin Is Required for
Skeletal Muscle Hypertrophy. The Journal ofBiological Chemistry. Vol 74 p21908-
21912
Dunn, S. E., Simard, A. R., Bassel-Duby, R., Williams, R. S., and Michel, R. N,
2001. Nerve Activity-dependent Modulation of Calcineurin Signaling in Adult Fast
and Slow Skeletal Muscle Fibers. Journal ofBiological Chemistiy, Vol 276 p.
45243-45254
Favier, F. B., Benoit H. and Freyssenet D., 2008. Cellular and molecular events
controlling skeletal muscle mass in response to altered use. Pflugers Arch - Eur J
Physiol. Vol 456 p.587-600
Friday, B. B., and Pavlath, G. K. 2001. A calcineurin- and NFAT-dependent pathway
regulates Myf5 gene expression in skeletal muscle reserve cells. Journal ofCell
Science, Vol 1 14 p.303-310
Gallagher, D., Visser, M., De Meersman R. E., Lveda D. S., Baumgartner R. N.,
Pierson R. N., Harris T., and Heymsfield, S. B., 1997. Appendicular skeletal muscle
mass: effects of age, gender, and ethnicity. Journal Applied Physiology. Vol 83,
p.229-239
Gilson, H., Schakman O., Combaret L., Lause P., Grobet L., Attaix D., Ketelslegers J.
M., and Thissen J. P., 2007. Myostatin Gene Deletion Prevents Glucocorticoid-
Induced Muscle Atrophy. Endocrinology. Vol.148 p.452-460
Gilson, H., Schakman O., Kalista S., Lause P., Tsuchida K., Thissen J.P., 2009.
Follistatin induces muscle hypertrophy through satellite cell proliferation and
inhibition of both myostatin and activin. Am JPhysiol Endocrinol Metab. Vol 297
p. 157- 164
Girgenrath, S., Song, K., and Whittemore, L., 2004. Loss of myostatin expression
alters fiber-type distribution and expression of myosin heavy chain isoforms in slow-
and fast-type skeletal muscle, Muscle Nerve. Vol 3 1 , p. 34-40
Haidet, A. M., Rizo L., Handy C, Umapathi P., Eagle A., Shilling C, Boue D.,
Martin P. T., Sahenk Z., Mendell J. R., and Kaspar B. K., 2008. Long-term
enhancement of skeletal muscle mass and strength by single gene administration of
myostatin inhibitors. Proceedings ofthe National Academy ofSciences. Vol.105
p.43 18-4322
82
Handschin, C, Chin S., Li P., Liu F., Maratos-Flier E., LeBrasseur N. K., Yan Z., and
Spiegelman B. M., 2007. Skeletal Muscle Fiber-type Switching, Exercise Intolerance,
and Myopathy in PGC-Ia Muscle specific Knock-out Animals. Journal ofBiological
Chemistry. Vol. 282 p. 30014-3002
Hennebry, A., Berry C, Siriett V., O'Callaghan P., Chau L., Watson T., Sharma M.
and Kambadur R., 2009. Myostatin regulates fibre type composition of skeletal
muscle by regulating MEF2 and MyoD gene expression. Am J Physiol Cell Physiol.
Vol 296 P.C525-34
Hill, J. J., Davies M. V., Pearson A. A., Wang J. H., Hewick R. M., Wolfman N. M.,
and Qiu Y., 2002. The Myostatin Propeptide and the Follistatin-related Gene Are
Inhibitory Binding Proteins of Myostatin in Normal Serum. Journal OfBiological
Chemistry. Vol. 277 p. 40735-40741
Hodge, M. R., Ranger, A. M., De La Brousse, F. C, Hoey T., Grusby, M. J., and
Glimche L.H., 1996. Hyperproliferation and Dysregulation of IL-4 Expression in NF-
ATp-Deficient Mice, Immunity. Vol 4 p3 97-405
Huet, C, Li, Z., Liu, H., Black, R. A., Gallian, M.F., and Engvall E., 2001. Skeletal
muscle cell hypertrophy induced by inhibitors of metalloproteases; myostatin as a
potential mediator. Am JPhysiol Cell Physiol. Vol.281 p. 1624-1 634
Ilham, C, Bruno, M., Picard, B., Reecy, J. M., Chevalier C, Hocquette J. F. and
Cassar-Malek ,1., 2009. Molecular profiles of Quadriceps muscle in myostatin-nu\\
mice reveal PI3K and apoptotic pathways as myostatin targets. BMC Genomics. Vol.
10p.l96
Joulia-Ekaza, D., and Cabello G., 2007. The myostatin gene: physiology and
pharmacological relevance. Current Opinion in Pharmacology. Vol.7 p.310-315
Joulia-Ekaza, D., Cabello G., 2006. Myostatin regulation ofmuscle development:
Molecular basis, natural mutations, physiopathological aspects. Experimental Cell
Research. Vol.312 p.2401-2414
Kääriäinen, J. M., Järvinen, M. T., Rantanen J., and Kalimo, H., 2000. Relation
between myofibers and connective tissue during muscle injury repair, ScandJMed
Sci Sports. Vol. 1 0, p.332-337
Kanisicak, O., Méndez J. J., Yamamoto S., Yamamoto M., and Goldhamer D. J.,
2009. Progenitors of skeletal muscle satellite cells express the muscle determination
gene, MyoD. Developmental Biology. Vol.332, p. 131-141
Kocamis, H., and Killefer, J, 2002. Myostatin expression and possible functions in
animal muscle. Domestic Animal Endocrinology. Vol.23 p.447-454
83
Kuang, S., and Rudnicki M. ?., 2007. The emerging biology of satellite cells and
their therapeutic potential. Trends in Molecular Medicine Vol.14 p. 82-91
Kuang, S., Kazuki K., Le Grand F., and Rudnicki M. A., 2007. Asymmetric Self-
Renewal and Commitment of Satellite Stem Cells in Muscle. Cell. Vol.129 p.999-
1010
Kuang, S., Gillespie M. A., and Rudnicki M. A., 2007. Niche Regulation of Muscle
Satellite Cell Self-Renewal and Differentiation. Cell Stem Cell. Vol.2 p.22-31
Le Grand, F., and Rudnicki M. A, 2007. Skeletal muscle satellite cells and adult
myogenesis. Curr Opin Cell Biol. Vol.19 p.628—633
Lee, SJ. and McPherron A. C, 2001. Regulation of myostatin activity and muscle
growth. PNAS. Vol. 98 p9306-931 1
Lee, S.J., 2007. Quadrupling Muscle Mass in Mice by Targeting TGF-ß Signalling
Pathways, PLoS ONE. Vol.2 p.789
Lin, S.Y., Morrison, J. R., Phillips, D. J., and de Kretser, D. M, 2003. Regulation of
ovarian function by the TGF-ß superfamily and follistatin. Reproduction. Vol. 126,
pl33-148
Macpherson, P., Cieslak, D., and Goldman, D., 2006. Myogenin-dependent nAChR
clustering in aneural myotubes, Molecular Cellular Neuroscience, Vol 31, p.649-660
Matsakas, A., Foster K., Otto A., Macharía R., Elashry M., Feist S., Graham L, Foster
H., Yaworsky P., Walsh F., Dickson G., Patel K., 2009. Molecular, cellular and
physiological investigation of myostatin propeptide-mediated muscle growth in adult
mice, Neuromuscular Disorders, Vol. 19 p.489-499
Manceau, M., Gros J., Savage K., 2008. Myostatin promotes the terminal
differentiation of embryonic muscle progenitors. Genes Dev. Vol.22 p.668-681
Marieb El. Essentials of Anatomy and Physiology, 8h Edition
McCroskery, S., Thomas M., Piatt L., Hennebry A., Nishimura T., McLeay L.,
Sharma, M., and Kambadur R., 2005. Improved muscle healing through enhanced
regeneration and reduced fibrosis in myostatin-null mice. Journal ofCell Science
Vol.1 18 p.3531-3541
McCroskery, S., Thomas M., Maxwell L., Sharma M., and Kambadur R., 2003.
Myostatin negatively regulates satellite cell activation and self-renewal. Journal of
Cell Biology. Vol. 1 62 p. 1 1 35- 1 1 47
84
McFarlane, C, Hennebry ?., Thomas M., Plummer E., Ling N., Sharma M.,
Kambadur R., 2008. Myostatin signals through Pax7 to regulate satellite cell self-
renewal, Experimental Cell Research. Vol.314 p.3 17-329
McFarlane, C, Langley B., Thomas M., Hennebry A., Plummer E., Nicholas G.,
McMahon C, Sharma M., Kambadur R., 2005. Proteolytic processing of myostatin is
auto-regulated during myogenesis, Developmental Biology Vol. 283 p.58 - 69
McPherron, A.C., Lawler, A.M., Lee, S.J, 1997. Regulation of skeletal muscle mass
in mice by a new TGF-ß superfamily member, Nature. Vol.387 p.83-90
Mendias, C. L., Marcin J. E., Calerdon D. R., and Faulkner J. A. 2006. Contractile
properties of EDL and soleus muscles of myostatin-deficient mice, JAppi Physiol
Vol.101 p.898-905
Mendias, C. L., Bakhurin K. L, and Faulkner J. A., 2008. Tendons of myostatin-
deficient mice are small, brittle, and hypocellular. Proceedings ofthe National
Academy ofSciences. Vol.105 p.388-393
Michel, R. N., Chin, E. R., Chakkalakal, J. V., Eibl, J. K., and Jasmin, B. J., 2007.
Ca/Calmodulin-based signalling in the regulation of the muscle fibre phenotype and
its therapeutic potential via modulation of utrophin A and myostatin expression,
Applied Physiology Nutrition Metabolism. Vol 32 p92 1-929
Morissette, M. R., Cook S. A., Buranasombati C, Rosenberg M. A., and Rosenzweig
?., 2009, Myostatin Inhibits IGF-I Induced Myotube Hypertrophy through Akt.
American Journal ofPhysiology Cell Physiology. Vol.297 p. 1 124-132
Mousavi, K., and Jasmin, B. J., 2006. BDNF Is Expressed in Skeletal Muscle Satellite
Cells and Inhibits Myogenic Differentiation, Journal ofNeuroscience, Vol. 26
p.5739-5749
Nadeau, Amelie, MD, and George Karpati, MD, 2008. Are Big Muscles Necessarily
Good Muscles?. Annals ofNeurology. Vol.63 p.543-545
Nader, Gustavo A., 2005. Molecular determinants of skeletal muscle mass: getting the
"AKT" together. The International Journal ofBiochemistry & Cell Biology Vol.37
p. 1985-1 996
Olguin, Hugo C, Bradley B. Olwin, 2004. Pax-7 up-regulation inhibits myogenesis
and cell cycle progression in satellite cells: a potential mechanism for self-renewal.
Developmental Biology 275, 375- 388
Olson, E. N. and Williams, R. S., 2000. Remodeling muscles with calcineurin,
BioEssays. Vol 22 p.510-519
85
Pehme, ?., Alev, K., Kaasik, P., Julkunen, ?., Seene, T., 2004. The effect of
mechanical loading on the MyHC synthesis rate and composition in rat plantaris
muscle, Physiology and Biochemistry. Vol.25, p. 332-338
Rodgers, B. D., and Garikipati D. K., 2008. Clinical, Agricultural, and Evolutionary
Biology of Myostatin: A Comparative Review, Endocrine Reviews. Vol.29 p.5 1 3-
534
Sugiura, T., Noritaka A., Mai N., Katsumasa G., Kunihiro S., Hisashi N., Toshitada
Y., and Powers, S. K., 2005. Changes in PKB/Akt and calcineurin signaling during
recovery in atrophied soleus muscle induced by unloading, Am JPhysiol Regul Integr
Comp Physiol. Vol. 288 p. 1273- 1278
Sakuma, K., Mai A., Nakashima H., Nakao R., Hirata M., Inashima S., Yamaguchi
A., Yasuhara M., 2008. Cyclosporin A modulates cellular localization of MEF2C
protein and blocks Wber hypertrophy in the overloaded soleus muscle of mice, Acta
Neuropathol. Vol. 1 1 5 p.663-674
Sakuma, K., Nakao R., Aoi W., Inashima S., Fujikawa T., Hirata M., Sano M.,
Yasuhara M., 2005. Cyclosporin A treatment upregulates IdI and Smad3 expression
and delays skeletal muscle regeneration. Acta Neuropathol Vol.1 10 p.269-280
Salerno, M. S., Thomas M., Forbes D., Watson T., Kambadur R., and Sharma M.,
2004. Molecular analysis of fiber type-specific expression of murine myostatin
promoter. Am JPhysiol Cell Physiol. Vol.287 p.1031-1040
Schneyer, A. L., Sidis Y., Gulati A., Sun J. L., Keutmann H., and Krasney P. A;
Differential Antagonism of Activin, Myostatin and GDFl 1 By Wild-type And Mutant
Follistatin. Endocrinology. Vol. 1 49 p.4589-4595
Seale, P., and Rudnicki M. A., 2000. A New Look at the Origin, Function, and
"Stem-Cell" Status of Muscle Satellite Cells, Developmental Biology. Vol.218 p. 1 15-
124
Seale, P., Sabourin L. A., Girgis-Gabardo A., Mansouri A., Gruss P., and Rudnicki
M. A., 2000. Pax7 Is Required for the Specification of Myogenic Satellite Cells. Cell.
Vol 102,p777-786
Shao, C, Liu M., Wu X., and Ding F., 2007. Time-dependent expression of myostatin
RNA transcript and protein in gastrocnemius muscle of mice after sciatic nerve
resection. Microsurgery. Vol.27 p.487-493
Shi, X., and Garry D. J., 2006. Muscle stem cells in development, regeneration, and
disease. Genes and Development. Vol.20 p. 1692- 1708
86
Steelman, C. ?., Recknor J. C, Nettleton D., and Reecy J. M., 2006. Transcriptional
profiling of myostatin-knockout mice implicates Wnt signaling in postnatal skeletal
muscle growth and hypertrophy. FASEB Journal, Vol. 20 p.580-582
Tsuchida, K., Masashi N., Akiyoshi U., Tatsuya M., and Xueling Cui., 2008. Signal
Transduction Pathway Through Activin Receptors as a Therapeutic Target of
Musculoskeletal Diseases and Cancer. Endocrine Journal. Vol 55 p. 1 1-21
Wagner, K. R., McPherron A. C, Wiriik N., and Lee S.J., 2002. Loss of Myostatin
Attenuates Severity of Muscular Dystrophy in mdx Mice. Ann Neurol. Vol.52 p.832-
836
Wang, J., Campos, B. A., Jamieson, G. A., Kaetzel, M. A., and Dedman, J. R., 1995.
Functional Elimination of Calmodulin within the Nucleus by Targeted Expression of
an Inhibitor Peptide, Journal ofBiological Chemistry. Vol 270 p.30245-30248
Wójcik, S. ?., Nogalska, W.K. Engel, Askanas V., 2008. Myostatin and its precursor
protein are increased in the skeletal muscle of patients with Type-II muscle fibre
atrophy. Folia Morphol. Vol.67 p. 1-7
Yafe, A., Shklover J., Weisman-Shomer P., Bengal E., and Fry M., 2008. Differential
binding of quadruplex structures of muscle-specific genes regulatory sequences by
MyoD, MRF4 and myogenin. Nucleic Acids Research, Vol. 36 p.39 16-3925
Zhang, Peng, Xiaoping Chen, Ming Fan, 2007. Signalling mechanisms involved in
disuse muscle atrophy. Medical Hypotheses Vol.69 p.3 10-321
Zhi-fang, Li, G. Diane Shelton, and Eva Engvall, 2005. Elimination of Myostatin
Does Not Combat Muscular Dystrophy in dy Mice but Increases Postnatal Lethality.





Non-Overloaded Control Mice Muscle Weights
Soleus
L (mg) R (mg) Avg
Avg
REL BW STD SE
F67-5 11.0 10.8 10.9 0.333333 32.7
G54-5 10.0 10.4 10.2 0.280992 36.3
C57 11.3 10.9 11.1 0.431907 25.7
AVG 10.7 0.348744 0.472582 0.272853
0.076629 0.044243
J91-4 16.5 17.5 17.0 0.420792 40.4
J92-1 17 16.8 16.9 0.478754 35.3
J90-2 13.3 13.5 13.4 0.470175 28.5













L (mg) R (mg)
Avg
ABS avg REL BW STD SE
F67-5 21.5 22.5 21.5 0.672783 32.7
G54-5 20.1 21.8 20.1 0.577135 36.3
C57 18.3 18.1 18.3 0.708171 25.7
AVG 20.0 0.652696 1.604161 0.92619
0.067788 0.039139
J91-4 43.2 41.9 43.2 1.053218 40.4
J92-1 38.5 34.7 38.5 1.036827 35.3
J90-2 30.1 31.2 30.1 1.075439 28.5









L (mg) R (mg) Avg
Avg
REL BW STD SE
F67-5 153 152 152.5 4.663609 32.7
G54-5 138.8 132.2 135.5 3.732782 36.3
C57 142.5 134.5 138.5 5.389105 25.7
AVG 142.2 4.595165 9.073772 5.238898
0.83028 0.479376
J91-4 320 314.7 317.4 7.855198 40.4
J92-1 269.6 275.2 272.4 7.716714 35.3
J90-2 221.1 216.4 218.8 7.675439 28.5
















REL BW STD SE
F67-5 54.4 55 54.7 1.672783 32.7
G54-5 49.7 45.3 47.5 1.30854 36.3
C57 60.1 55.2 57.7 2.243191 25.7
AVG 53.3 1.741504 5.221191 3.014544
0.4711 0.271998
J91-4 118 110.6 114.3 2.829208 40.4
J92-1 95.4 93.1 94.3 2.669972 35.3
J90-2 75.8 79.4 77.6 2.722807 28.5
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L (mg) R (mg) Avg
Avg
REL BW STD SE
F67-5 13.6 13.4 13.5 0.412844 32.7
G54-5 11.3 10.4 10.9 0.298898 36.3
C57 11.3 10.6 11.0 0.42607 25.7
AVG 11.8 0.379271 1.501943 0.867173
0.069918 0.040368
J91-4 22.8 23.5 23.2 0.57302 40.4
J92-1 19.5 20.7 20.1 0.569405 35.3
J90-2 14.9 16 15.5 0.542105 28.5













Extracted Mice for Overload Project









F67-5wt non-OV 21.5 22.5 32.7 22.0 0.67278287
G54-5wt non-OV 20.1 21.8 36.3 21.0 0.57713499
c57wt non-OV 18.3 18.1 25.7 18.2 0.70817121
J91-4ko non-OV 43.2 41.9 40.4 42.6 1.05321782
J92-lko non-OV 38.5 34.7 35.3 36.6 1.0368272
J90-2ko non-OV 30.1 31.2 28.5 30.7 1.0754386
F74-lwt 3day-OV 29.0 32.1 33.5 30.6 0.9119403
E65-lwt 3day-OV 19.4 21.9 23.1 20.7 0.89393939
Jacklwt 3day-OV 30.5 28.8 29.9 29.7 0.9916388
J104-lko 3day-OV 46.4 20.1 35.3 33.3 0.94192635
J107-lko 3day-OV 27.2 34.1 26.8 30.7 1.14365672
J110-2ko 3day-OV 39.9 39.3 36.8 39.6 1.07608696
c57stk 2wk-OV 53.5 58.0 32.0 55.8 1.7421875
F70-2wt 2wk-OV 26.0 27.1 24.3 26.6 1.09259259
J95-lko 2wk-OV 60.3 38.8 29.2 49.6 1.69691781
J95-2ko 2wk-OV 48.0 55.8 37.0 51.9 1.4027027
E55-lwt 6wk-OV 49.4 49.7 29.6 49.6 1.67398649
B122-lwt 6wk-OV 32.2 42.2 33.5 37.2 1.11044776
J85-lko 6wk-OV 38.0 53.0 32.5 45.5 1.4
J85-3ko 6wk-OV 64.7 63.8 33.2 64.3 1.93524096
Absolute Mass Table
non-OV 3day-OV 2wk-OV 6wk-OV
Mstn+/+ 20.38333 25.60000 41.15000 43.37500
STD 1.96235 7.00036 20.64752 8.73277
SE 1.13300 4.95075 14.60221 6.17593
Mstn-/- 36.60000 31.95000 50.72500 54.87500
STD 5.95000 1.83848 1.66170 13.25825
SE 3.43533 1.30020 1.17518 9.37642
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Relative Mass Table
non-OV 3day-OV 2wk-OV 6wk-OV
Mstn+/+ 0.65270 0.90294 1.41739 1.39222
STD 0.06779 0.01273 0.45933 0.39848
SE 0.03914 0.00735 0.26520 0.23007
Mstn-/- 1.05516 0.90294 1.54981 1.66762
STD 0.01938 0.14264 0.20804 0.37847
SE 0.01119 0.08236 0.12012 0.21852
B) Physiological Measurement Summaries
ctl Pia
Whole
Midbelly Avg cell size (µ??2 # (midbelly/cell avg)
C57stk 1649659 1743 946
F67-5 1700053 1586.12266 1072
G54-5 1448761 1558.450339 930
AVG 1599491 1629 983
STD 132945 100 78
J90-2 2545629 2203.630481 1155
J91-4 2932506 2061.665061 1422
J92-1 2667716 1984.718709 1344
AVG 2715284 2083 1307




Midbelly Avg cell size (µ??2 # (midbelly/cell avg)
F74-1 2553059 1755 1455
E65-1 (F) 1822437 1580 1153
AVG 2187748 1668 1304
STD 516628 124 213
J 104-1 4779264 1915 2356











OV Whole Midbelly Avg cell size (µ??2) # (midbelly/cell avg)
C57stk 2580354 2330 1108
F70-2 1977533 1654 1196
AVG 2278943.5 1992 1152
STD 426259 478 62
J95-1 3211185 2372 1354
J95-2 3161743 1855 1705
AVG 3186464 2113 1529
STD 34961 366 248
6wk-
OV Whole Midbelly (µ??2) Avg cell size (µ?t?2 # (midbelly/cell avg)
E55-1 3750789 2504 1498
B122-1 2591831 2548 1017
AVG 3171310 2526 1258
STD 819507 32 340
J85-1 3019782 2499 1208
J85-3 3632605 2460 1476
AVG 3326193.5 2480 1342
STD 433331 28 190
C) Cross-sectional Area Tables














1013.991 1089.932 1653.362 2461.128 2472.82
262.1776 287.3973 352.1136 173.2435 417.0976
85 54 58 137





















Proportion 2.729277 | 2.651515 | 20.67918 | 23.72571 | 24.9303 | 6.163934 | 19.12009
l/IIA IIA IIA/1 IX MX IIX/IIB IIB
G54-5 avg 650.6865 841.0505 1188.497 1549.289 2120.062
STD 126.9817 155.2522 257.9973 228.2416 434.1008
tot count 28 15 38 18 98
Proportion 13.87429 8.06982 19.52496 9.124347 49.40658
I l/IIA IIA IIA/1 IX MX IIX/IIB IIB
Mstn+/+ 869.145 984.6865 857.7012 1016.632 1568.851 2162.494 2326.956
STD 62.33077 256.1688 197.9476 252.1736 350.2702 275.3164 452.1057
SE 35.98774 147.9035 114.2885 145.5968 202.2346 158.9587 261.031
tot count 13 188 152 186 46 307
proportions 1.002352 0.883838 19.97936 15.70154 20.47733 5.774601 36.18097
prop STD 1.501996 1.530853 5.78699 7.835319 4.061412 3.560414 15.50322
prop SE 0.867204 0.883864 3.341218 4.523856 2.344926 2.055666 8.951054
l/IIA IIA IIA/1 IX IIX IIX/IIB IIB
J91-4 avg 857.8112 756.4217 1531.941 2804.212 2680.399
STD 56.12335 206.3799 459.1561 571.788 544.3885
tot count 76 70 10 170
Proportion 0.564972 21.85293 21.21517 2.830763 53.53617
l/IIA IIA IIA/1 IX IIX IIX/IIB IIB
J92-1 avg 941.0764 1054.084 1573.833 2252.221 2678.834
STD 173.4316 228.0514 494.1454 276.1031 535.0594
tot count 60 53 10 166
Proportion 0.950617 20.3565 18.65127 3.352814 56.68879
l/IIA IIA IIA/1 IX MX IIX/IIB IIB
J90-2 avg 1170.375 1328.396 2103.974 2903.344 2588.63
STD 279.4339 374.9638 510.8226 984.2706 492.1801
tot count 0 46 21 62 138














STD N/A N/A 169.6629 269.7983 488.0414 610.7206 523.876
SE N/A N/A 97.95781 155.7727 281.7791 352.61 302.4688
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tot count 51 157 185 29 474
proportions 6.204243 16.80191 20.58894 3.107311 53.29759
prop STD 9.435496 7.490134 1.712686 0.262407 3.516567
prop SE 5.447746 4.324558 0.988849 0.151505 2.03035
I l/l IA MA IIA/IIX MX IIX/IIB IB
E65-1 AVG 860.2907 1010.039 1247.419 1650.833 1896.019 2058.606
avg STD 422.701 355.7286 464.8197 485.994 692.2469 711.3196
tot Count 13 50 29 42 86
Proportions 5.608411 21.96415 12.69898 18.29543 4.049068 37.38396
l/IIA HA IIA/IIX HX IIX/IIB HB
F74-1 AVG 972.1299 811.4489 1003.5 1596.135 2359.61 2647.27
avg STD 312.8189 439.9762 586.8981 1072.345 925.6269
tot Count 66 21 46 10 69
Proportions 0.510204 31.13844 9.418717 21.7272 4.908322 32.29712
I l/IIA HA IIA/IIX HX IIX/IIB HB
Mstn+/+ 860.2907 972.1299 910.7441 1125.459 1623.484 2127.814 2352.938
avg STD 422.701 #DIV/0! 334.2737 452.3979 536.4461 882.2961 818.4733
tot Count 13 116 50 88 19 155
Proportions 2.804205 0.255102 26.55129 11.05885 20.01131 4.478695 34.84054
Prop STD 3.965745 0.360769 6.487203 2.319499 2.426629 0.607584 3.59694
Prop SE 2.804629 0.255141 4.587838 1.640381 1.716145 0.429692 2.543805
l/IIA HA IIA/IIX HX IIX/IIB HB
J104-1 AVG 1056.845 1289.447 1621.419 2378.848 2575.143
avg STD 453.5549 483.976 645.5184 837.8236 876.4732
tot Count 12 27 50 19 108
Proportions 5.789955 13.17287 23.70575 8.766632 48.56479
l/IIA HA IIA/IIX HX IIX/IIB HB
J 107-1 AVG 1076.792 1346.13 2053.751 2415.956 2387.552
avg STD 359.6519 477.6955 764.5228 1248.897 807.3472
tot Count 33 43 31 108
Proportions 15.16171 19.80786 14.00208 2.409836 48.61851
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I ?/??? IIA IIA/IIX MX IIX/IIB IIB
Mstn-/- #DIV/0! #DIV/0! 1066.818 1317.788 1837.585 2397.402 2481.347
avg STD #DIV/0! #DIV/0! 406.6034 480.8357 705.0206 1043.36 841.9102
tot Count 0 0 45 70 81 24 216
Proportions 10.47583 16.49037 18.85392 5.588234 48.59165
Prop STD 6.626833 4.691649 6.861528 4.494934 0.03798
Prop SE 4.686586 3.317998 4.852566 3.178878 0.02686
l/IIA MA IIA/IIX MX IIX/IIB HB
c57 2wk
AVG 1858.311 1951.112 2210.293 2800.153 3076.823
avg STD 697.2627 678.6943 932.2079 998.1036 1027.682
tot Count 34 13 31 16 23
Proportions 27.88595 11.3286 25.92403 14.06367 20.79775
I l/IIA MA IIA/IIX MX IIX/IIB MB
F70-2 AVG 1347.904 1076.178 1291.664 1656.298 2154.118 2181.174 2091.549
avg STD 605.0757 531.2672 554.1779 656.2436 730.644 707.9747 1005.613
tot Count 8 15 66 20 43 11 27
Proportions 4.007243 7.430032 33.82825 10.38272 23.22856 5.91886 15.20433
I l/IIA ha IIA/IIX MX IIX/IIB MB
Mstn+/+ 1347.904 1076.178 1574.987 1803.705 2182.205 2490.663 2584.186
avg STD 605.0757 531.2672 625.7203 667.4689 831.4259 853.0392 1016.648
tot Count 8 15 100 33 74 27 50
Proportions 2.003621 3.715016 30.8571 10.85566 24.57629 9.991267 18.00104
Prop STD 2.833549 5.253826 4.20184 0.668833 1.905985 5.759254 3.955144
Prop SE 2.003924 3.715577 2.971599 0.473008 1.347938 4.073022 2.797131
l/IIA IIA IIA/IIX nx IIX/IIB MB
J95-1 AVG 1113.263 1600.061 1910.088 2730.934 2838.135
avg STD 443.0009 556.656 730.5794 901.2256 968.1791
tot Count 13 25 34 24 81
Proportions 7.301742 13.80076 19.69544 13.52825 45.67381
l/IIA HA IIA/IIX MX IIX/IIB IB














Proportions 13.335 11.09574 12.20367 14.3996 48.33706
?/??? HA IIA/IIX NX IIX/IIB HB
Mstn-/- #DIV/0! #DIV/0! 1043.241 1483.201 1698.708 2477.347 2574.838
avg STD #DIV/0! #DIV/0! 497.3965 587.2028 642.1732 932.704 899.2966
tot Count 0 0 34 43 53 47 157
Proportions 0 0 10.31837 12.44825 15.94955 13.96392 47.00544
Prop STD #DIV/0! #DIV/0! 4.266159 1.912735 5.297484 0.616135 1.883204
Prop SE 0 0 3.017085 1.352713 3.746452 0.435739 1.331828
I l/l IA IIA IIA/IIX MX IIX/IIB HB
B122-1 AVG 1471.781 1656.937 1770.921 2328.831 2920.012 3551.029 4010.377
avg STD 694.8431 977.4109 725.7374 912.6857 1056.674 2091.4 1546.105
tot Count 16 25 12 37 16
Proportions 12.94347 2.358674 21.19518 10.6384 33.20541 5.291179 14.36769
I ?/?? IIA IIA/IIX HX IIX/IIB IB
E55-1 AVG 1706.104 1851.792 1987.267 2394.988 2905.957 2838.368 3368.681
avg STD 627.4839 767.85 880.0732 944.8316 990.0099 1398.745 984.6017
tot Count 16 10 49 10 26 12 36
Proportions 10.19843 5.643879 31.83454 6.319321 18.02672 6.194296 21.78281
I l/l IA IIA IIA/IIX HX IIX/IIB IIB
Mstn+/+ 1588.943 1754.365 1879.094 2361.909 2912.985 3194.698 3689.529
avg STD 661.1635 872.6304 802.9053 928.7587 1023.342 1745.072 1265.353
tot Count 32 13 74 22 63 18 52
Proportions 11.57095 4.001277 26.51486 8.478861 25.61606 5.742738 18.07525
Prop STD 1.941034 2.322991 7.523168 3.054051 10.73296 0.6386 5.243283
Prop SE 1.372725 1.64285 5.320487 2.159867 7.590493 0.451626 3.708121
I l/IIA IIA IIA/IIX HX IIX/IIB IIB
J85-1 AVG
avg STD
#DIV/0! #DIV/0! 1319.167 1552.109 2086.074 2664.036 2950.479
#DIV/0! #DIV/0! 358.5177 343.3715 598.8195 463.7639 433.8026
tot Count
Proportions
0 0 23 34 46 32 89















avg STD #DIV/0! #DIV/0! 348.8753 325.111 527.7478 746.7788
tot Count 0 0 25 20 34 25
Proportions 14.44134 12.04268 20.5176 15.49085
I l/IIA MA IIA/IIX UX IIX/IIB
Mstn-/- #DIV/0! #DIV/0! 1339.7 1560.547 2182.176 2771.932
avg STD #DIV/0! #DIV/0! 353.6965 334.2412 563.2836 605.2713
tot Count 0 0 48 54 80 57
Proportions 13.28447 13.84924 20.46933 15.11614
Prop STD 1.636071 2.554856 0.068255 0.529912




Samples 28S Atrogin-1 Atrgn:28S
C57STK 238 120 50.42017
E62-2 229 115 50.21834
J92-1 264 132 50
J97-1 253 147 58.10277
F74-1 292 110 37.67123
E65-1 248 108 43.54839
J 104-1 292 79 27.05479
J 107-1 248 125 50.40323
C57STK 254 60 23.62205
F70-2 285 79 27.7193
J95-1 257 48 18.67704
J95-2 260 64 24.61538
E55-1 257 72 28.01556
B122-1 268 82 30.59701
J85-1 260 76 29.23077
J85-3 257 106 41.24514
Samples non-OV 3d-OV 2wk-OV 6wk-OV
Mstn+/+ 50.31925 40.60981 25.67067 29.30629
STD 0.142714 4.155776 2.897194 1.825361
SE 0.100929 2.939021 2.048935 1.29092
Mstn-/- 54.05138 38.72901 21.64621 35.23795
STD 5.729521 16.50983 4.199042 8.49544
SE 4.051995 11.67598 2.969619 6.008091
Samples 28S Calcineurin A Cn A:28S
C57STK 238 235 98.7395
E62-2 229 248 108.2969
J92-1 264 289 109.4697
J97-1 253 271 107.1146
F74-1 292 364 124.6575
E65-1 248 333 134.2742
J 104-1 292 294 100.6849
J 107-1 248 267 107.6613
C57STK 254 206 81.10236
F70-2 285 187 65.61404
J95-1 257 183 71.20623
J95-2 260 171 65.76923
E55-1 257 156 60.70039
B122-1 268 161 60.07463
J85-1 260 196 75.38462
100
J85-3 257 214 83.26848
Samples non-OV 3d-OV 2wk-OV 6wk-OV
Mstn+/+ 103.5182 129.4659 73.3582 60.38751
STD 6.758136 6.800005 10.9519 0.442481
SE 4.779445 4.809056 7.745333 0.312928
Mstn-/- 108.2922 104.1731 68.48773 79.32655
STD 1.665288 4.933031 3.844536 5.574736
SE 1.177714 3.488706 2.718908 3.942529
Samples 28S Foil ¡statin Foll:28S
C57STK 238 27 11.34454
E62-2 229 46 20.08734
J92-1 264 32 12.12121
J97-1 253 45 17.78656
F74-1 292 240 82.19178
E65-1 248 243 97.98387
J 104-1 292 62 21 .23288
J 107-1 248 74 29.83871
C57STK 254 121 47.6378
F70-2 285 106 37.19298
J95-1 257 50 19.45525
J95-2 260 35 13.46154
E55-1 257 125 48.63813
B 122-1 268 78 29.10448
J85-1 260 96 36.92308
J85-3 257 0
Samples non-OV 3d-OV 2wk-OV 6wk-OV
Mstn+/+ 15.71594 90.08783 42.41539 38.8713
STD 6.182092 11.16669 7.385598 13.81238
SE 4.372059 7.897238 5.223195 9.768302
Mstn-/- 14.95389 25.53579 16.4584 18.46154
STD 4.006007 6.085243 4.238196 26.10856
SE 2.833102 4.303566 2.99731 18.46433
Samples 28S Myogenin Mgn:28S
C57STK 238 28 11.76471
E62-2 229 32 13.9738
J92-1 264 47 17.80303
J97-1 253 38 15.01976
F74-1 292 84 28.76712
E65-1 248 76 30.64516
J 104-1 292 132 45.20548
J 107-1 248 141 56.85484
C57STK 254 163 64.17323
F70-2 285 164 57.54386
J95-1 257 248 96.49805
J95-2 260 258 99.23077
E55-1 257 69 26.84825
B122-1 268 69 25.74627
J85-1 260 94 36.15385
J85-3 257 101 39.29961
Samples non-OV 3d-OV 2wk-OV 6wk-OV
Mstn+/+ 12.86925 29.70614 60.85854 26.29726
STD 1.562065 1.327973 4.687672 0.779218
SE 1.104713 0.939161 3.315185 0.551073
Mstn-/- 16.4114 51.03016 97.86441 37.72673
STD 1.968067 8.237341 1.932321 2.224392
SE 1.391844 5.825559 1.366564 1.57312
Samples 28S BDNF BDNF:28S
C57STK 238 245 102.9411765
E62-2 229 265 115.720524
J92-1 264 558 211.3636364
J97-1 253 531 209.8814229
F74-1 292 111 38.01369863
E65-1 248 115 46.37096774
J 104-1 292 55 18.83561644
J107-1 248 72 29.03225806
C57STK 254 91 35.82677165
F70-2 285 88 30.87719298
J95-1 257 87 33.85214008
J95-2 260 71 27.30769231
E55-1 257 176 68.48249027
B122-1 268 156 58.20895522
J85-1 260 106 40.76923077
J85-3 257 94 36.57587549
Samples non-OV 3d-OV 2wk-OV 6wk-OV
Mstn+/+ 109.3309 42.19233 33.35198 63.34572
STD 9.036363 5.909482 3.499881 7.264486
SE 6.390639 4.179266 2.475163 5.137543
Mstn-/- 210.6225 23.93394 30.57992 38.67255
STD 1.048083 7.210114 4.627623 2.96515



















non-OV 3d-OV 2wk-OV 6wk-OV
Mstn+/+ 764 40 63 73
SEWT 23 1
Mstn+/+ 1 0.05239 0.08186 0.094957
SEWT 0.029474 0.00131 0.005895 0.001965
Samples 28S MSTN Ratio (x1 00) Ratio
C69-1 177 216 122.0338983 1.220339
C70-2 217 189 87.09677419 0.870968
D84-1 218 300 137.6146789 1.376147
C68-1 221 237 107.239819 1 .072398
C69-3 244 232 95.08196721 0.95082
C71-2 265 252 95.09433962 0.950943
D101-2 245 163 66.53061224 0.665306
D101-5 271 126 46.49446494 0.464945
D101-6 236 108 45.76271186 0.457627
Strain CD1 wt TnIs-PVHA Tnls-CamBP
AVG 115.5817838 99.13870861 52.92926302
STD 25.86961558 7.015770125 11.78479492
SE 14.93626765 4.050675592 6.804154109
Strain CD1 TnIs-PVHA Tnls-CamBP
AVG 1.155817838 0.991387086 0.52929263
STD 0.258696156 0.070157701 0.117847949
SE 0.149362677 0.040506756 0.068041541





Blab/c 2 N95-2 Balb/c 2 N95-2 Balb/c 2 N95-2
535 1785 475 500 1.15 3.44
1614 454 488




Balb/c 1 N95-3 Balb/c 1 N95-3 Balb/c 1 N95-3
73793 250078 46574 56985 1.42 3.96
61514 205797 48466 58041




Balb/c 3 NN20-1 Balb/c 3 NN20-1 Balb/c 3 NN20-1
146343 620050 20135 53118 3.59 11.11
612472 21738 57802









a-tubulin myogen ? ? MgniTubulin
?60-2 wt 3587 79040 22.0351268
c57 wt 3475 84053 24.1879137
J97-2 ko 3233 230919 71.4256109














Pax7G Pax7R Pax7 avg STD SE
wt non-Ov 526 356 441 120.2082 85.01284
ko non-Ov 426 443 434.5 12.02082 8.501284
wt 3d-Ov 1105 1067 1086 26.87006 19.00287
ko 3d-Ov 758 467 612.5 205.7681 145.522
wt 2wk-Ov 708 737 722.5 20.5061 14.50219
ko 2wk-Ov 505 995 750 346.4823 245.037
wt 6wk-Ov 367 912 639.5 385.3732 272.5412
ko 6wk-Ov 326 738 532 291.328 206.0311
Absoulte Calculations
non-OV 3day-OV 2wk-OV 6wk-OV
Mstn+/+ 441 1086 722.5 639.5
SE 85.01284 19.00287 14.50219 272.5412
Mstn-/- 434.5 612.5 750 532





Mstn+/+ 0.600916 1.690981 1.180335
SE 0.01934 0.039252 0.106907
Mstn-/- 0.681884 1 .098022 1.192264





non-OV 3d OV 2wkOV 6wkOV
wt averages 1599491 2187748 2278944 3171310
STD 132945 516628 426259 819507
SE 76758 365366 301456 579567
KO averages 2715284 4328500 3186464 3326194
STD 197776 637477 34961 433331
SE 114190 450832 24725 306458
non-OV 3d OV 2wkOV 6wkOV
Mstn+/+ 1.60 2.19 2.28 3.17
STD 0.13 0.52 0.43 0.82
SE 0.08 0.37 0.30 0.58
Mstn-/- 2.72 4.33 3.19 3.33
STD 0.20 0.64 0.03 0.43
SE 0.11 0.45 0.02 0.31
t-Test: Two-Sample Assuming Unequal Variances





































































































































































































































































non-OV 3d OV 2wkOV 6wkOV
Mstn+/+ 983 1304 1143 1258
STD 77.75871 213.1431 270.5704 340.1817
SE 44.89533 150.7377 191.3511 240.5811
Mstn-/- 1307 2190 1529 1342
STD 137.3657 234.3274 248.085 189.6311

































































































Mstn-/- #DIV/0! #DIV/0! #DIV/0!
2wk avg std SE
Mstn+/+ 1347.904 #DIV/0! #DIV/0!
Mstn-/- #DIV/0! #DIV/0! #DIV/0!
2wk avg std SE
Mstn+/+ 1588.943 165.6919681 117.17961























MyHC I-IIA Expressing Myofíbres
control
avg std SE
Mstn+/+ 984.6865 #DIV/0! #DIV/0!
Mstn-/- #DIV/0! #DIV/0! #DIV/0!
3day avg std SE
Mstn+/+ 972.1299 #DIV/0! #DIV/0!
Mstn-/- #DIV/0! #DIV/0! #DIV/0!
2wk avg std SE
Mstn+/+ 1076.178 #DIV/0! #DIV/0!
Mstn-/- #DIV/0! #DIV/0! #DIV/0!
2wk avg std SE
Mstn+/+ 1754.365 137.7837927 97.4426











2wk-0V 1076.178 #DIV/0! #DIV/0!
6wk-OV 1754.365 #DIV/0! 97.4426 #DIV/0!
MyHC HA Expressing Myofibres
control avg std SE
Mstn+/+ 857.701224 186.8884636 107.9032699
Mstn-/- 989.754232 161.8678158 93.4571685
3day avg std SE
Mstn+/+ 910.744148 140.4246873 99.45091168
Mstn-/- 1066.81848 14.10400384 9.974543026
2wk avg std SE
Mstn+/+ 1574.9872 400.6797524 283.3661616
Mstn-/- 1043.24144 99.02594585 70.03249353
2wk avg std SE
Mstn+/+ 1879.09393 152.9801176 108.1896164


























t-Test: Two-Sample Assuming Unequal Variances
























t-Test: Two-Sample Assuming Unequal Variances
























t-Test: Two-Sample Assuming Unequal Variances
























t-Test: Two-Sample Assuming Unequal Variances
























MyHC IIA-IIX Expressing Myofibres
control
avg std SE
Mstn+/+ 1016.632 152.746937 88.19107216
Mstn-/- 1046.301 286.0665858 165.1654652
3day avg std SE
Mstn+/+ 1125.459 172.4762868 122.1503448
Mstn-/- 1317.788 40.08101587 28.34583866
2wk avg std SE
Mstn+/+ 1803.705 208.4649972 147.4292766
Mstn-/- 1483.201 165.2644518 116.8772643
2wk avg std SE
Mstn+/+ 2361.909 46.77992022 33.08339478


























t-Test: Two-Sample Assuming Unequal Variances
























t-Test: Two-Sample Assuming Unequal Variances
116
























t-Test: Two-Sample Assuming Unequal Variances








t Critical one-tail 2.91998558
P(T<=t) two-tail 0.230528094
t Critical two-tail 4.30265273
t-Test: Two-Sample Assuming Unequal Variances








t Critical one-tail 6.313751514
P(T<=t) two-tail 0.027103286
t Critical two-tail 12.70620473
MyHC HX Expressing Myofìbres
control
avg Std SE
Mstn+/+ 1568.851 345.9296734 199.7284488
Mstn-/- 1736.583 318.8588204 184.0986261
3day avg Std SE
Mstn+/+ 1623.484 38.6768235 27.39151806
Mstn-/- 1837.585 305.7046471 216.1984774
2wk avg Std SE
Mstn+/+ 2182.205 39.72142014 28.09152768
Mstn-/- 1698.708 298.9371099 211.4123833
2wk avg Std SE
Mstn+/+ 2912.985 9.938127952 7.028379033


























t-Test: Two-Sample Assuming Unequal Variances
























t-Test: Two-Sample Assuming Unequal Variances

































t Critical one-tail 6.313751514
P(T<=t) two-tail 0.264433826
t Critical two-tail 12.70620473
t-Test: Two-Sample Assuming Unequal Variances








t Critical one-tail 6.313751514
P(T<=t) two-tail 0.083458899
t Critical two-tail 12.70620473
MyHC IIX-lIB Expressing Myofibres
control
avg std SE
Mstn+/+ 2162.494 531.1107786 306.6459461
Mstn-/- 2653.259 350.8280756 202.5566256
3day avg std SE
Mstn+/+ 2127.814 327.8081041 232.1587139
Mstn-/- 2397.402 26.23911556 18.55665881
2wk avg std SE
Mstn+/+ 2490.663 437.684337 309.5363062
Mstn-/- 2477.347 358.6270818 253.6259418
2wk avg std SE
Mstn+/+ 3194.698 503.9273521 356.384266



















































t-Test: Two-Sample Assuming Unequal Variances

























t-Test: Two-Sample Assuming Unequal Variances
WT IIX/B 2wk-








t Critical one-tail 2.91998558
P(T<=t) two-tail 0.976472887
t Critical two-tail 4.30265273
t-Test: Two-Sample Assuming Unequal Variances
WT IIX/B 6wk-








t Critical one-tail 6.313751514
P(T<=t) two-tail 0.459651156
t Critical two-tail 12.70620473
MyHC IIB Expressing Myofibres
control
avg std SE
Mstn+/+ 2326.956 184.1277506 106.3093248
Mstn-/- 2649.288 52.53707233 30.33318264
3day avg std SE
Mstn+/+ 2352.938 416.2489113 294.7938465
Mstn-/- 2481.347 132.6465391 93.8094336
2wk avg std SE
Mstn+/+ 2584.186 696.693323 492.7109781
Mstn-/- 2574.838 372.3573566 263.3361786
2wk avg std SE
Mstn+/+ 3689.529 453.7480049 320.8967502


























t-Test: Two-Sample Assuming Unequal Variances
























t-Test: Two-Sample Assuming Unequal Variances
























t-Test: Two-Sample Assuming Unequal Variances








t Critical one-tail 2.91998558
P(T<=t) two-tail 0.988167683
t Critical two-tail 4.30265273
t-Test: Two-Sample Assuming Unequal Variances








t Critical one-tail 6.313751514
P(T<=t) two-tail 0.298345158
t Critical two-tail 12.70620473











N of Rows in Working Data
File
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User-defined missing values are treated
as missing.
Statistics are based on all cases with



































Dependent Variable:Relative CnA Expression




























Tests of Between-Subjects Effects
Dependent Variable:Relative CnA Expression
Source
Type III Sum of































a. R Squared = .974 (Adjusted R Squared = .952)
Estimated Marginal Means
Group
Dependent Variable:Relative CnA Expression
Group Mean Std. Error
95% Confidence Interval












































Dependent Variable:Relative CnA Expression
(I) Group (J) Group
Mean
Difference (l-J) Std. Error Sig.
95% Confidence Interval
Lower Bound Upper Bound




































































































































































mstn-/- 6wk-ov 75.50 13.777 .008 20.98 130.02


























































































































































































































































































































































































































































































































































































































































































































































































































Based on observed means.





























































Sig. .254 .066 .423
348.50
.051
Means for groups in homogeneous subsets are displayed.
Based on observed means.
The error term is Mean Square(Error) = 189.813.
a. Uses Harmonic Mean Sample Size = 2.000.
b. Alpha = .05.
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User-defined missing values are treated
as missing.
Statistics are based on all cases with
valid data for all variables in the model.































Dependent Variable:Relative Atrogin Expression
































Tests of Between-Subjects Effects
Dependent Variable:Relative Atrogin Expression
Source
Type III Sum of






























a. R Squared = .840 (Adjusted R Squared = .700)
Estimated Marginal Means
Group
Dependent Variable:Relative Atrogin Expression
Group Mean Std. Error
95% Confidence Interval













































Dependent Variable:Relative Atrogin Expression
(I) Group (J) Group
Mean
Difference (l-J) Std. Error Sig.
95% Confidence Interval
Lower Bound Upper Bound
























































































































































































































































































































































































































































































































































































































































































































































































































































































Based on observed means.
The error term is Mean Square( Error) = 249.188.




















































Means for groups in homogeneous subsets are displayed.
Based on observed means.
The error term is Mean Square(Error) = 249.188.
a. Uses Harmonic Mean Sample Size = 2.000.
b. Alpha = .05.











N of Rows in Working Data
File
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User-defined missing values are treated
as missing.
Statistics are based on all cases with
valid data for all variables in the model.































Dependent Variable:Relative Follistatin Expression



































Tests of Between-Subjects Effects
Dependent Variable:Relative Follistatin Expression
Source
Type III Sum of






























a. R Squared = .914 (Adjusted R Squared = .840)
Estimated Marginal Means
Group
Dependent Variable:Relative Follistatin Expression
Group Mean Std. Errar
95% Confidence Interval












































Dependent Variable:Relative Follistatin Expression
(I) Group (J) Group
Mean
Difference (l-J) Std. Error Sig.
95% Confidence Interval
Lower Bound Upper Bound















































































































































































































































































































































































































































































































































































































































































































































































































































































Based on observed means.
The error term is Mean Square(Error) = 784.875.
*. The mean difference is significant at the .05 level.
Homogeneous Subsets
Relative Fol I ¡stati ? Expression
Group
Subset



































Means for groups ¡? homogeneous subsets are displayed.
Based on observed means.
The error term is Mean Square(Error) = 784.875.
a. Uses Harmonic Mean Sample Size = 2.000.
b. Alpha = .05.











N of Rows in Working Data
File
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User-defined missing values are treated
as missing.
Statistics are based on all cases with



































Dependent Variable:Relative Myogenin Expression




























Tests of Between-Subjects Effects
Dependent VariableiRelative Myogenin Expression
Source
Type III Sum of































a. R Squared = .997 (Adjusted R Squared = .995)
Estimated Marginal Means
Group
Dependent Variable: Relative Myogenin Expression
Group Mean Std. Error
95% Confidence Interval













































Dependent Variable:Relative Myogenin Expression
(I) Group (J) Group
Mean
Difference (l-J) Std. Error Sig.
95% Confidence Interval
Lower Bound Upper Bound




































































































































































mstrW- 6wk-ov 39.00 4.950 .001 19.41






















































































































































































































































































































































































































































































































































































































































































































































































































Based on observed means.
The error term is Mean Square(Error) = 24.500.
*. The mean difference is significant at the .05 level.
Homogeneous Subsets
Relative Myogen i ? Expression
Group N
Subset






























Sig. .542 .671 .217 1 .000
Means for groups in homogeneous subsets are displayed.
Based on observed means.
The error term is Mean Square(Error) = 24.500.
a. Uses Harmonic Mean Sample Size = 2.000.
b. Alpha = .05.
Relative Myogenin Expression
Group















Means for groups in homogeneous subsets are displayed.
Based on observed means.
The error term is Mean Square(Error) = 24.500.
a. Uses Harmonic Mean Sample Size = 2.000.
b. Alpha = .05.











N of Rows in Working Data
File
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User-defined missing values are treated
as missing.
Statistics are based on all cases with



































Dependent Variable:Relative BDNF Expression




























Tests of Between-Subjects Effects
Dependent Variable:Relative BDNF Expression
Source
Type III Sum of































a. R Squared = .997 (Adjusted R Squared = .994)
Estimated Marginal Means
Group
Dependent Variable:Relative BDNF Expression
Group Mean Std. Error
95% Confidence Interval













































Dependent Variable:Relative BDNF Expression
(I) Group (J) Group
Mean
Difference (l-J) Std. Error Sig.
95% Confidence Interval
Lower Bound Upper Bound




































































































































































mstrW- 6wk-ov -36.50 1 1 .840 .153 -83.35 10.35









































































































































































































































































































































































































































































































































































































































































































































































































































Based on observed means.
The error term is Mean Square(Error) = 140.188.












































Sig. .112 .082 1.000
544.50
1.000
Means for groups in homogeneous subsets are displayed.
Based on observed means.
The error term is Mean Square(Error) = 140.188.
a. Uses Harmonic Mean Sample Size = 2.000.
b. Alpha = .05.
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User-defined missing values are treated
as missing.
Statistics are based on all cases with
valid data for all variables in the model.































Dependent Variable:Relative Mstn Expression
















Tests of Between-Subjects Effects
Dependent Variable:Relative Mstn Expression
198
Source
Type III Sum of




























a. R Squared = .999 (Adjusted R Squared = .998)
Estimated Marginal Means
Group
Dependent Variable:Relative Mstn Expression
Group Mean Std. Error
95% Confidence Interval

























Dependent Variable:Relative Mstn Expression
(I) Group (J) Group
Mean Difference
(l-J) Std. Error
Tukey HSD mstn+/+ non-ov mstn+/+ 3d-ov
mstn+/+ 2wk-ov
mstn+/+ 6wk-ov
mstn+/+ 3d-ov mstn+/+ non-ov
mstn+/+ 2wk-ov
mstn+/+ 6wk-ov






























Scheffe mstn+/+ non-ov mstn+/+ 3d-ov
mstn+/+ 2wk-ov
mstn+/+ 6wk-ov
mstn+/+ 3d-ov mstn+/+ non-ov
mstn+/+ 2wk-ov
mstn+/+ 6wk-ov
mstn+/+ 2wk-ov mstn+/+ non-ov
mstn+/+ 3d-ov
mstn+/+ 6wk-ov



























LSD mstn+/+ non-ov mstn+/+ 3d-ov
mstn+/+ 2wk-ov
mstn+/+ 6wk-ov















mstn+/+ 2wk-ov mstn+/+ non-ov
mstn+/+ 3d-ov
mstn+/+ 6wk-ov





















Based on observed means.
The error term is Mean Square(Error) = 264.875.
*. The mean difference is significant at the .05 level.
Multiple Comparisons
Dependent Variable.Relative Mstn Expression
(I) Group (J) Group
95% Confidence Interval
Lower Bound Upper Bound
Tukey HSD mstn+/+ non-ov mstn+/+ 3d-ov
mstn+/+ 2wk-ov
mstn+/+ 6wk-ov
mstn+/+ 3d-ov mstn+/+ non-ov
mstn+/+ 2wk-ov
mstn+/+ 6wk-ov































Scheffe mstn+/+ non-ov mstn+/+ 3d-ov
mstn+/+ 2wk-ov
mstn+/+ 6wk-ov
mstn+/+ 3d-ov mstn+/+ non-ov
mstn+/+ 2wk-ov
mstn+/+ 6wk-ov
mstn+/+ 2wk-ov mstn+/+ non-ov
mstn+/+ 3d-ov
mstn+/+ 6wk-ov



























LSD mstn+/+ non-ov mstn+/+ 3d-ov
mstn+/+ 2wk-ov
mstn+/+ 6wk-ov











mstn+/+ 2wk-ov mstn+/+ non-ov
mstn+/+ 3d-ov
mstn+/+ 6wk-ov



















Based on observed means.



























Means for groups in homogeneous subsets are displayed.
Based on observed means.
The error term is Mean Square(Error) = 264.875.
a. Uses Harmonic Mean Sample Size = 2.000.
b. Alpha = .05.
